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resumo 
 
 
A doença de Alzheimer (AD) é uma doença neurodegenerativa 
progressiva caracterizada pela presença de placas de amilóide 
extracelulares (placas senis) e tranças neurofibrilhares intracelulares 
formadas pela proteína TAU hiperfosforilada. A proteína TAU quando 
hiperfosforilada perde a capacidade de se ligar a microtúbulos e pode ser 
libertada para fluidos periféricos. Este processo leva à degradação 
neuronal e à morte neuronal. A fosforilação na treonina 231 tem-se 
demonstrado ser específica para a AD e preceder a formação de 
filamentos helicoidais emparelhados no cérebro humano. Para melhor 
perceber a função deste resíduo e a contribuição para a localização da 
TAU, analisámos células SH-SY5Y indiferenciadas e células 
diferenciadas, pela adição de ácido retinoico (RA). O tratamento com RA 
aumentou a expressão de TAU fosforilada na Thr231 (TAUpThr231) 
conforme determinado por Western blot. Explorámos ainda a fosforilação 
da TAU por imunocitoquímica e percebemos que em células SH-SY5Y 
indiferenciadas, a phosphoTAU231 estava localizada principalmente no 
núcleo. Em contraste, TAU e phosphoTAU231 foram redistribuídas para 
as dendrites e citosol das células SH-SY5Y diferenciadas pelo ácido 
retinoico (RA). Para avaliar o potencial deste resíduo como biomarcador; 
medimos TAUpThr231 em CSF por meio de um imunoensaio enzimático 
em sanduíche e observámos que a proporção de níveis de TAUpThr231 
/ TAU discriminou de forma significativa o grupo AD do grupo não-AD. 
Essas descobertas podem indicar que os níveis da relação TAUpThr231 
/ t-TAU podem ser um marcador valioso para o diagnóstico clínico de AD, 
independentemente da idade e do género. 
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abstract 
 
Alzheimer's disease (AD) is a progressive neurodegenerative disorder 
characterized by the presence of extracellular amyloid plaques (senile 
plaques) and intracellular neurofibrillary tangles formed by 
hyperphosphorylated TAU protein. TAU protein when 
hyperphosphorylated loses the ability to bind to microtubules and can be 
released into peripheral fluids. This process leads to neuronal 
degradation and neuronal death. Phosphorylation at threonine 231 has 
been shown to be specific for AD and to precede assembly of paired 
helical filaments in the human brain. In order to understand more about 
this residue we analysed SH-SY5Y cells undifferentiated and in 
differentiated cells induced by retinoic acid (RA). Treatment with RA 
increased expression of TAU phosphorylated at Thr231 (TAUpThr231) 
as determined by Western blot analysis. We further explored TAU 
phosphorylation by immunocytochemistry and noticed that in 
undifferentiated SH-SY5Y cells, TAUpThr231 was located mainly in the 
nucleus. In contrast, TAU and TAUpThr231 was redistributed to the 
neurites and in the soma of SH-SY5Y cells, which were induced to 
differentiate by retinoic acid (RA). In order to evaluate the potential of 
TAUpThr231 as a biomarker, we measured TAUpThr231 in CSF by a 
sandwich enzyme immunoassay and observed that the ratio of 
TAUpThr231/TAU levels discriminated significantly the AD group for the 
non-AD group. These findings indicate that TAUpThr231/t-TAU ratio 
levels may be a valuable marker for the clinical diagnosis of AD, 
irrespective of age and gender. 
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1. Introduction         
1.1 Alzheimer’s disease (AD) 
 
As ageing of the current population rises, the incidence of neurodegenerative diseases has 
continuously increased. There are approximately 47 million people with dementia worldwide and 
this number is estimated to rise to 131 million by 2050 (1). Amongst the neurodegenerative 
disorders, Alzheimer´s Disease (AD) is the most common age-related dementia, generally affecting 
people over 65 years old. It currently affects about 24 million people worldwide, 7–8 million in 
Europe, 4–5 million in the USA, and 90 000 people in Portugal (2). 
Alois Alzheimer initially categorized AD in 1906 after analyzing a post-mortem sample of a 51-
year-old woman with signs of paranoia, sleep and memory impairment, confusion, disorientation, 
hallucinations and aggressive behaviour. Alois described the disease as a deterioration of the 
patient’s memory, communication and social and physical abilities (3–5). 
 
1.1.1 Characterizing Alzheimer's Disease  
 
AD is characterized by progressive and insidious dysfunction affecting various cognitive and 
functional domains of the central nervous system leading to neuronal cell death, vascular 
dysfunction, and inflammatory responses. These changes are of sufficient severity to interfere with 
the person's ability to perform daily activities and to be self-sufficient (6).   
The clinical phenotype of AD can be divided into two main stages. The first consists of a 
progressive and rather isolated amnestic syndrome in relation to the early involvement of the medial 
temporal structures. The second is characterised by the addition and the development of cognitive 
symptoms in the domain of executive (conceptualisation, judgment, problem solving) and 
instrumental (anomia, apraxia, face or object recognition) functions and become increasingly more 
evident, leading to severe cognitive, functional impairment and psycho-behavioural changes, due to 
the increased burden and progression of neuronal lesions to the neocortical areas (6,7). All these 
symptoms progressively impact on the autonomy of the patient defining the dementia stage. 
Patients in more advanced states become very susceptible to infections, pneumonia and 
decubitus ulcers. The life expectancy after diagnosis of AD is usually between 4 to 8 years, yet some 
patients can live as long as 20 years with the disease (8). 
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1.1.2 Neuropathological hallmarks of Alzheimer’s Disease 
 
AD patients’ brains are normally characterized by severe neuronal loss confined to specific 
areas or layers of the cortex leading to cortical atrophy in the form of gyral shrinkage, widening of 
the sulci and enlargement of the ventricles (9).  
The primary brain regions affected are the hippocampus, the neocortex and the entorhinal 
cortex (10). With disease progression, the neurodegeneration progresses to the temporal and 
parietal lobes (entorhinal cortex, hippocampal formations, parahippocampal gyrus) areas known to 
be critical for long-term episodic memory, and, in some patients, even to the frontal and occipital 
lobes (11,12).  
AD hallmarks pathologies include the extracellular deposition of Aβ peptides (amyloid 
plaques, designated as senile plaques (SP)), intracellular accumulation of TAU protein within neurons 
(neurofibrillary tangles/NFTs) and dendrites (neuropil threads) (Figure 1), and neuritic plaques in 
brain parenchyma, inducing defects of synaptic connections (6).  
(A)                                 (B) 
   
Figure 1. Neuropathological AD alterations A. Senile Plaques B. Neurofibrillary tangles (Taken from (13))  
  
 Amyloid plaques are formed by the progressive accumulation of beta-amyloid (Aβ) outside 
the neurons (Figure 1A). Aβ deposits are morphologically diverse and result from a peptide that 
arises following sequential cleavage of the transmembrane amyloid precursor protein (APP) by α or 
β and γ secretases. The processed Aβ can accumulate extracellularly, where it aggregates into 
plaques (6).  
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 APP undergoes cleavage during its transport through the axons to the synaptic terminals, 
where it accumulates in high concentrations. When APP is cleaved by the α-secretase, a soluble N-
terminal amino fragment (sAPPα) and a C-terminal fragment (CTF) are released (Figure 2). Aβ is 
generated when the precursor protein is alternatively cleaved by a β-secretase in the N-terminal 
domain (Figure 2), releasing a soluble N-terminal fragment (sAPPβ), and then followed by γ-secretase 
cleavage at position 40 or 42 of the C-terminal end. The majority of Abeta peptides are 40 amino 
acids long (Aβ40). However, the Aβ42, although less abundant, is more prone to aggregate, being 
the most abundant species in the amyloid plaques (14). The physiological function of APP still 
remains largely undetermined, but it has been suggested to have a role in neurite outgrowth and 
synaptogenesis, transmembrane signal transduction, neuronal protein trafficking along the axon, cell 
adhesion, calcium metabolism, and several more (reviewed in (15)). 
 
 
Figure 2. Proteolytic processing of APP. A. Non-amyloidogenic pathway. B. Amyloidogenic pathway. (Taken from (16)) 
  
 The neurotoxicity of these aggregates leads to the formation of SP which in turn lead to 
modifications in synaptic plasticity and neuronal integrity (17). This leads to a greater selective 
vulnerability of neurons which seems to contribute strongly to a cascade of events (amyloid cascade), 
culminating in processes of neurodegeneration and regional atrophy that appear to negatively affect 
other proteins, as is the case of TAU protein (18).  
 TAU is a microtubule-associated protein, responsible for the stabilization of microtubules. 
When hyperphosphorylated and misfolded, TAU is sequestered into paired helical filaments (PHF) 
and creates the intraneuronal aggregates know as neurofibrillary tangles (NFTs). In brains of AD 
patients, neurofibrillary tangles can also appear as “ghost cells” with the shape of dead neurons 
(Figure 1B). Consequently, the axonal cytoskeleton is disturbed, axonal transport disrupted and 
neuronal viability compromised (19). TAU is further discussed below. 
6 
 
1.1.3 Risk factors contributing to AD 
 
AD can be early-onset/familial (EOAD) and late-onset/sporadic (LOAD). Most cases of AD 
occur late in life (> 65 years) as a late-onset AD. The exact causes of the late-onset AD are still 
imperceptible but there are a large number of risk factors that appear to contribute to the 
development of AD. The single most important risk factor is age, but there are also environmental, 
mental and lifestyle changes, female sex, low educational level, cardiovascular disease, diabetes 
mellitus type 2 (T2DM)  and genetic risk factors (14,20). 
T2DM is a risk factor based on pathology of glucose utilization. This pathology is the 
consequence of a disturbance of insulin-related mechanisms leading to a brain insulin resistance. 
Moreover, it is possible that therapeutic options utilised today for diabetes treatment may also have 
an effect on the risk for dementia. The contribution of T2DM and insulin-resistant brain state to 
cerebrovascular disturbances cannot be neglected (21).  
Genetic factors account for up to 80% of the attributable risk in common AD forms. The 
familial AD usually develops before 65 years of age and accounts for only a small proportion (<1%) 
of AD cases. It is caused mainly by overproduction of Aβ caused by mutations or duplications in an 
APP gene or genes encoding presenilin 1 (PSEN1) or presenilin 2 (PSEN2), which are essential 
components of the γ-secretase complex responsible for the cleavage and release of Aβ (14).  
Genetically, APP is located on chromosome 21 (21q21.2-3) and is expressed ubiquitously in 
all tissue types in a specific cell form. The APP gene transcribes a transmembrane protein that 
undergoes post-translational proteolytic processing by alpha, beta and gamma secretases. Alpha-
secretase generates a soluble amyloid protein, whereas beta and gamma secretases lead to both the 
processing and the amyloidogenic production of Aβ. These 2 processing paths are mutually exclusive. 
APP mutations result in preferential processing of APP through the amyloidogenic pathway, resulting 
in a low concentration of alpha-sAPP in CSF which may reflect in an increased production of Aβ (22).  
Down syndrome also affects the risk of AD. The additional copy of chromosome 21, where 
the  APP gene is located, appears to increase the amount of Aβ fragments in the brain (23). Thus a 
direct ‘load’ effect is evident, whereby an extra copy of APP is associated with more Aβ production. 
PSEN1 and PSEN2 are components of the γ secretase complex, responsible for the gamma-
secretase-mediated proteolytic cleavage of the C-terminal transmembrane fragments of APP to 
produce Aβ. PSEN1 and PSEN2 mutations are associated with early-onset familial Alzheimer’s 
disease because it can alter production of Aβ42 which leads to plaque formation more easily than 
with Aβ40. It has been reported that PSEN mutations may cause Alzheimer's disease through a 
deleterious gain of function that increases the Aβ42 amount deposited in the brain (24).  
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Contrary to EOAD, LOAD is considered a multifactorial disease, meaning that the individual 
disease risk is determined by genetic, environmental and demographic factors and the interaction 
between them.  The strongest genetic risk factor for LOAD is the APOE gene encoding the 
Apolipoprotein (ApoE). ApoE is a glycoprotein for the transport of triglycerides, phospholipids, and 
cholesterol in cells, present in the SPs and can influence the formation of neuritic plaques. After an 
injury, ApoE is produced by astrocytes in the CNS to promote the protection of neurons or to repair 
the injured neurons. It also acts as a chaperone for Aβ by binding the peptide and altering its 
conformation, influencing its clearance, by transporting the peptide from the brain to the periphery, 
and its ability to aggregate (25).  
In the APOE gene, there are three major allelic variants (-ε2, -ε3, and -ε4). These allelic 
variants lead to three different protein isoforms (ApoE2, ApoE3 and ApoE4) that differ in their 
structure, their ability to bind lipids, receptors, and Aβ, and consequently, have different transport 
efficiencies (25).  A strong genetic association between the APOE-ε4 allele and the susceptibility of 
LOAD has been identified, with one APOE-ε4 allele increasing AD risk by 3-fold, and two APOE-ε4 
alleles increasing AD risk by 12-fold (26,27). For APOE-ε2, compelling evidence supports a protective 
effect and a delaying effect on age of disease onset (28). APOE-ε3 is thought to be a neutral allele in 
respect to its effect upon susceptibility to AD (29). 
Although APOE is the strongest genetic risk factor for LOAD, the effect of APOE-ε4 on AD 
susceptibility explains only a small fraction of the estimated heritability leaving most of it 
unexplained. In recent years, genome-wide association studies (GWAS) have identified several 
genes/loci, which together with APOE4, contribute to a high proportion of the genetic risk of AD. 
These include signals close to, or within, candidate genes such as CLU (clusterin), PICALM 
(phosphatidylinositol binding clathrin assembly protein), CR1 (complement component (3b/4b) 
receptor 1), BIN1 (bridging integrator 1), MS4A6A/MS4A4E (membrane-spanning 4-domains, 
subfamily A, members 6A and 4E), CD33 (CD33 molecule), CD2AP (CD2- associated protein), ABCA7 
(ATP-binding cassette, subfamily A (ABC1), Member 7), EPHA1 (EPH receptor A1) and ATP5H/KCTD2 
genes (review in (30–32)). 
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1.1.4 Diagnosing AD  
 
Currently, the clinical diagnosis of AD is considered a two-step procedure with an initial 
identification of a dementia syndrome based on  a detailed patients’ personal and family medical 
history, followed by the exclusion of other possible aetiologies of dementia syndrome with  physical 
and neurological examinations, laboratory tests and neuropsychological tests such as 
blood/cerebrospinal fluid (CSF) investigations for ruling out infectious, inflammatory or metabolic 
diseases and brain neuroimageing (CT scan or MRI) for excluding vascular diseases, infarcts and/or 
cerebral haemorrhages, brains tumours, hydrocephalus and similar conditions (13).   
Neuroimageing techniques are also used as tools for AD diagnosis, namely computerized 
tomography (CT), positron emission tomography (PET) and magnetic resonance imageing (MRI). MRI 
enables detailed visualization and volumetric measures of the medial temporal lobe structures to 
detect a substantial loss of neurons, synapses, dendritic branches, and axons, as well as the 
expansion of the cerebrospinal fluid (CSF) spaces and alterations in the medial temporal lobe during 
the progression of the neurodegenerative disease (33). PET is an imageing technique that is often 
used with different marker compounds such as fluorodeoxyglucose (FDG) or the Pittsburgh 
Compound B (PIB) (Figure 3) (34). FDG-PET can measure glucose uptake in brain metabolism. In AD, 
a decrease in uptake of FDG-PET is an indicator of synaptic dysfunction. Pittsburgh Compound B is 
an amyloid radiotracer that binds specifically to beta-amyloid allowing the visualization of amyloid 
plaques in the cerebral cortex of patients with Alzheimer's. It has better ability to differentiate 
patients (with MCI, AD, and healthy controls) than FDG-PET since this technique cannot identify the 
abnormal protein deposits that can cause the disease (35).  
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Figure 3. Amyloid deposition (upper panel, white arrows) and glucose hypometabolism (lower panel, red arrows) in an AD 
patient. Images from [11C]PIB-PET and [18F]FDG-PET, respectively. SUVR, standardized uptake value ratio, presented as 
ratios to cerebellum) (36). 
 
This type of diagnosis can only detect the disease in a late and already symptomatic state, 
making it necessary to find ways to achieve an earlier diagnosis. Currently, the quantification of AD 
biomarkers such as Aβ and TAU, both total and phosphorylated TAU, in the CSF is the gold standard 
to detect early AD patients, as reviewed later in this dissertation (37).  
The identification of the disease is still not perfect, and for some cases, the final confirmation 
arrives only with the pathological or molecular post-mortem analysis of brain tissue, where the 
presence of the senile plaques and neurofibrillary tangles can be confirmed (33). In the absence of 
such histological evidence, the clinical diagnosis of AD can only be probable and should only be made 
when the disease is advanced and reaches the threshold of dementia. For the diagnosis of probable 
AD, a dementia syndrome must be established by clinical examination, documented by mental status 
questionnaire, and confirmed by neuropsychological testing. 
AD is a complex disease and has no cure since the treatment is significantly impaired by the 
lack of accessible diagnosis that can reliably and differently detect the risk or presence of the disease 
(38). Current therapies for AD focus on symptomatic and neuroprotective approaches to delay the 
disease (review in (39)). Therefore, the development of objective biomarkers that are precise 
indicators of the pathogenic processes of AD is extremely important to detect the preclinical stages 
of AD for the early diagnosis, to monitor the progression of neurodegenerative diseases, to evaluate 
the responses to therapies and stratify the diseases in their different subtypes. 
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1.2 Biomarkers of AD 
 
The Biomarkers Working Group of the National Institutes of Health (2001) described a 
biomarker as “A characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (40). 
Ideally, an AD a diagnostic biomarker should meet a number of criteria, including being 
linked to fundamental features of the neuropathology, being validated in neuropathologically 
confirmed cases, being able to detect the disease early in its course and to distinguish it from other 
dementias, having a fast, simple, accurate, non-invasive and inexpensive detection, and not be 
influenced by symptomatic drug treatments (35). 
Before an AD biomarker could be validated it should have sensitivity and specificity of over 
85%, it should have prior probability (the background prevalence of the disease in the population 
tested) and positive predictive value over 80% (percentage of people who are positive for the 
biomarker and have definite the disease at autopsy) (41). 
Currently, the most interesting applications of biomarkers is achieving pre-symptomatic 
diagnosis of neuropsychiatric disorders, which would allow early treatment strategies at a time when 
more than 50% of degenerating types of neurons are still available and can be rescued, providing 
evidence for effectiveness of therapies and differentiate certain disorder subtypes, as in the case of 
‘dementias’ (42). 
The development of objective biomarkers that are precise indicators of the pathogenic 
processes of AD - degeneration of neurons and their synapses, senile plaques and neurofibrillary 
entanglements - is extremely important to detect the preclinical stages of AD for the early diagnosis, 
to monitor the progression of neurodegenerative diseases, to evaluate the responses to therapies 
and to stratify the disease in its different subtypes (41). There is an urgent need for a simple 
screening procedure that can identify patients with AD in a differential, inexpensive and non-invasive 
manner.  
Blood is the ideal fluid for biomarkers evaluation, because it can be easily collected and have 
circulated through all the organs, contains secreted proteins. Changes in the concentrations of 
biomarkers in the blood may thus reflect changes in the disease state (33). For these reasons, the 
identification of novel and valid biomarkers in the blood is highly desirable and can become an 
essential tool for diagnosing AD. 
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1.2.1 Neurochemical AD Biomarkers  
 
The most recognized biomarkers for AD are found in CSF. These include changes in levels of 
Aβ peptides as well as hyperphosphorylated and total TAU protein (43). These particular changes are 
detectable in the early stages of dementia, as well as in individuals with mild cognitive impairment 
(MCI) who are at high risk of transitioning to AD. 
The Aβ peptides (Aβ1−40/Aβ1−42) are key molecules in the pathogenesis of AD, being the 
main constituent of SP. The decrease in Aβ42 concentration in CSF, but not in Aβ40 concentration, 
is considered a reliable diagnostic biomarker of AD. There are several potential mechanisms that try 
to explain this decrease of Aβ42 CSF concentrations in AD. One of these possible explanations could 
be a hypothetical decrease in the Aβ generation. This, however, stays in disagreement with the 
increased of the Aβ42 in the brain tissue (42). Another mechanism might be Aβ42 increased 
degradation, however, this should affect not only Aβ42 but also other Aβ peptides, at least Aβ40, 
since it is known that both peptides are largely metabolized by the same enzymes, also it should lead 
to the decrease of the formation of Aβ42 deposits in the brain parenchyma, and should prevent 
formation of the plaques. The next potential explanation is the increased Aβ42 clearance from the 
brain tissue to the blood across the blood-brain barrier. This would lead to the decreased amount of 
the Aβ42 molecules in the brain parenchyma and correspondingly less Aβ42 molecules could enter 
the CSF, but it was reported a decreased Aβ42 concentrations and/or Aβ42/40 ratios in the blood of 
AD patients or subjects at AD risk (44). Finally, there is a very interesting, hypothesis that the CSF 
concentrations of Aβ42 in AD patients only seems decreased, because the accumulation of Aβ42 
monomers into soluble oligomers leads to masking of the epitopes for the antibodies used in the 
ligand-based analytical methods. Indeed, increased concentrations of Aβ oligomers were reported, 
in the CSF of AD patients (44).  
Irrespective of the cause of decreased Aβ42 concentration in CSF, sensitivity and specificity 
of Aβ42 alone to distinguish AD from elderly controls were 78% and 81%, respectively (45). 
Better diagnostic performance of the Aβ42/40 ratio compared to the Aβ42 concentration 
might then be explained by the assumption that the subjects with either extraordinary low or 
extraordinary high concentrations of total Aβ peptides in the CSF characterise also with the 
respectively low or high Aβ42 (46). In such a case, a normalisation of the Aβ42 concentration by the 
application of the Aβ42/40 ratio, instead of the Aβ42 alone, improves the interpretation of the 
biomarkers. This decrease in Aβ42/Aβ40ratios in CSF most likely reflects the precipitation of Aβ42 
into SPs in the cerebral parenchyma (35).  
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The microtubule-associated protein TAU is the major component of intraneuronal NFTs 
observed in AD, frontotemporal dementia and in a group of more than 20 other Tauopathies. TAU 
protein (described in detail below) undergoes chemical changes that make it hyperphosphorylated, 
converting TAU from a normal functional protein to a neurotoxic protein, giving rise to neurofibrillary 
tangles (35).  
In AD, TAU concentrations tend to increase and although this is not a specific biomarker for 
AD, it is clinically associated with the severity of the disease. TAU is generally thought of as an 
intracellular protein which is released only upon axonal degradation and neuronal death, into the 
extracellular space. Thus TAU can then be transported to the peripheral fluids, making it detectable 
in peripheral bodily fluids such as CSF, plasma and/or serum (33). Abnormal concentrations of 
phosphorylated TAU protein (pTAU) in CSF have been proposed as a biomarker of AD since many 
neurodegenerative diseases can be distinguished by the set of TAU isoforms that accumulate in 
neurons (47). CSF TAU provides a useful marker of TAU pathology and can be used to monitor the 
efficacy of disease-modifying therapies (48). 
Currently, no biomarker meets the criteria of an ideal biomarker for AD, as the CSF is only 
assessable by lumbar puncture, which is still considered a relatively invasive practice that may cause 
discomfort to the patient and present some side effects. Nevertheless, CSF alterations are, at least 
currently, the first that can be observed in the disease process. The combination of three CSF 
biomarkers, namely TAU, pTAU181 and Aβ42 are still the best available markers, with a sensitivity of 
68% (95% CI 45–86%) and a specificity of 97% (95% CI 83–100%) to detect incipient AD among 
patients fulfiling the criteria for MCI (49,50). 
An algorithm has been proposed to interpret the levels of these biomarkers, called the 
Erlangen Score Algorithm (Figure 4). In brief, depending on the concentrations of the biomarkers, 
the numeric score is given, and the final sum (in the range 0–4 points) defines the categorisation of 
a given patient into one of the groups with different probability of AD pathology, which is eventually 
presented to the physician on the CSF integrated report (36,51). 
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 Aβ Normal (0) Aβ in Border 
Zone (+1) 
Aβ Pathologic 
(+2) 
TAU/pTAU Normal (0) 0 1 2 
TAU/pTAU in Border Zone (+1) 1 2 3 
TAU/pTAU Pathologic (+2) 2 3 4 
 
Figure 4. Erlanger Score. Erlangen Score is the sum of the scores for A biomarkers (0, normal; 1, borderline pathological; 
2, pathological) and TAU/pTAU biomarkers (0, normal; 1, borderline pathological; 2, pathological), always in relation to a 
given laboratory’s cut-offs. Depending on the total score, NDD is interpreted as: 0, neurochemically normal; 1, AD 
neurochemically improbable; 2–3, AD neurochemically possible; 4, AD neurochemically probable. (Taken from (36)) 
 
 
If the results of Aβ and TAU/pTAU are pathological, the overall result is interpreted as a 
neurochemically probable AD. 
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1.3 Microtubule-Associated Protein TAU 
 
The microtubule-associated protein TAU is quite abundant in the CNS’s neurons, especially in 
the distal termination of the axon and is important for the neuronal morphogenesis, brain 
development, and is involved in the regulation of microtubule dynamics (52). TAU changes such as 
abnormal cleavage and phosphorylation are a major component of intraneuronal aggregates 
observed in Alzheimer’s disease and other Tauopathies. The excessive phosphorylation of TAU 
detaches the protein from the microtubule causing microtubule destabilization (53). This alteration 
of microtubule equilibrium may result in axonal transport disturbances. 
TAU proteins are part of the microtubule-associated proteins (MAP) family and they are 
mainly detected in the axons of neurons, in the cytosol, in association with plasma membrane 
components and also in the nuclei of neurons. Non-neuronal cells like glial cells can also have traces 
of TAU, but mainly in pathological conditions (54). 
 
1.3.1 Gene and Protein Structure 
 
The human MAPT gene (codes for TAU protein) is located on the long arm of chromosome 
17, at band position 17q21. The TAU primary transcript comprises 16 exons and codes a total of six 
different mRNA species that are translated in six different isoforms of TAU with a range from 352 to 
441 amino acids, expressed in the adult human CNS (55) via alternative splicing (54). 
Brain TAU proteins have two domains: the projection domain and the microtubule-binding 
domain (Figure 5). The projection domain in the N-terminal region can be subdivided into an acidic 
region, which is encoded by exons 1–5 and a proline-rich region encoded by exon 7 and the first half 
of exon 9. This domain is responsible for the interactions with proteins associated with the neural 
plasma membrane and cytoplasmatic organelles and determines spacings between axonal 
microtubules. The microtubule-binding domain is subdivided into a region responsible for TAU 
binding with microtubules which are encoded by exons 9–12 and contains four repeat domains R1, 
R2, R3, and R4 also called MBDs (microtubule-binding domains) and a short C-terminal region which 
is encoded by exon 13 (56). As its name suggests, this domain is responsible for the binding of TAU 
to microtubules, especially through the repeat domains which are also responsible for promoting 
microtubule polymerization and stabilization (54). 
In the human brain, TAU proteins are a family of six isoforms, which range from 352 to 441 
amino acids (55), all of which are phosphorylated by glycogen synthase kinase 3 (GSK 3) (57). They 
differ from each other by the presence of either three (3R) or four (4R) conservative tubulin binding 
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repeats of 31–32 amino acids in the carboxy-terminal (C-terminal) part of the molecule and the 
absence (0N) or presence of one (1N),  or two (2N) inserts (29 or 58 amino acids) at the amino-
terminal (N-terminal) part (55). Thus, the longest isoforms in the CNS has four repeats and two 
inserts (441 residues), and the shortest isoform has three repeats and no inserts (352 residues) 
(Figure 5). 
 
 
   
Figure 5. Schematic representation of the human TAU gene, mRNA and different protein isoforms. The human TAU gene 
is located over 100kb on the long arm of chromosome 17 at position 17q21. It contains 16 exons; exon -1 is a part of the 
promoter. The TAU primary transcript contains 13 exons since exons 4A, 6 and 8 are not transcribed in human. Exons -1 
and 14 are transcribed but not translated. Exons 1, 4, 5, 7, 9, 11, 12, 13 are constitutive, and exons 2, 3 and 10 are 
alternatively spliced, giving rise to six different mRNAs, translated in six different TAU isoforms. These isoforms differ by 
the absence or presence of one or two 29 amino acids inserts encoded by exon 2 and 3 in the amino-terminal part, in 
combination with either three (R1, R3 and R4) or four (R1, R2, R3 and R4) repeat-regions in the carboxyl-terminal part. 
(taken from (54)) 
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The length of the projection domain further increases the diversity of TAU isoforms, by the 
number of repeat motifs, depending on exon alternative splicing and by various post-translational 
modifications. Each of these isoforms is likely to have particular physiological roles since they are 
differentially expressed during development.  
 
1.3.2 TAU Function in the CNS 
 
The physiological role of TAU is still not fully understood. Some studies suggest that one of 
the major biological functions of TAU is to promote microtubule assembly and stability in axons, due 
to their C-terminal microtubule-binding domain, which is essential for axonal transport, and might 
be involved in the creation and maintenance of neuronal polarity.  The N-terminal region jointly with 
the proline-rich domain creates projections from the microtubules’ surface to adjacent 
microtubules, binding the neural plasma membrane components. This suggests that TAU functions 
as a linker protein between both, therefore, contributing to the parallel ordered organization of 
microtubules in axons (58). TAU proteins are also involved in promoting microtubule nucleation, 
growth and bundling, and it is hypothesized that phosphorylation of the TAU molecule is an 
important factor in regulating TAU-microtubule interaction (reviewed in (59)).  
 
1.3.3 Post-translational modifications of TAU protein 
 
TAU protein, like many other proteins that are implicated in human disease, undergoes 
various post-translational modifications, including phosphorylation, glycosylation, ubiquitination, 
glycation, truncation, nitration, among others. An increased amount of the modified TAU has been 
found in a large number of neurodegenerative disorders (60). 
Glycosylation is an enzymatic process through which a covalent attachment of 
oligosaccharides to the side chain of polypeptides is formed. There are two types of glycosylation, 
N- and O-glycosylation, according to the nature of glycosidic bonds.  N- Glycosylation results from 
the attachment of sugars are linked to the amide group of the asparagine, while O- glycosylation is 
characterized by the addition of an O-linked N-acetylglucosamine (O-GlcNac) residue to the hydroxyl 
group of serine or threonine near the proline residue (56). In AD brains, the level of N-Glycosylation 
is enhanced and the level of O-GlcNac is decreased. Furthermore, it is believed that O-glycosylation 
may protect TAU from hyperphosphorylation and prevent, consequently, NFT formation (60). 
Glycation refers to a non-enzymatic linkage of a reducing sugar to the amino side chain of a 
polypeptide. In TAU isolated from PHF glycation can be present whereas no glycan has been detected 
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in normal TAU. Glycation is involved in the early disease process and appears to enhance the 
formation of PHF and its aggregation into more complex aggregates. Moreover, it has been found 
that the glycated TAU can disturb neuronal function by generating oxygen free radicals (61). 
Ubiquitination is the specific binding of a 76-amino acid protein, ubiquitin, on proteins to 
signal for their degradation in an ATP-dependent manner by the UPS (ubiquitin–proteasome-
system). In non-pathological conditions, TAU exists as an unfolded protein and it can be ubiquitinated 
and proteolytically processed by UPS. In AD, high levels of ubiquitinated TAU can be found in 
aberrant aggregates or in some types of paired helical filaments (61).  
TAU truncation consists of the cleavage of TAU that occurs at the glutamic acid residue 391. 
These truncated TAU proteins are conformationally different enhancing their capacity to form 
aggregates and contributing to the execution of neuronal apoptosis (61).   
Nitration is the addition of nitrogen dioxide to a tyrosine of an organic molecule and it has 
been suggested to be increased in AD brains (56). TAU nitration is involved in TAU aggregation and 
may represent oxidative damage of the brain as the accumulation of oxidants may be important for 
the nitration of TAU in AD brains (60). 
 
1.3.3.1 TAU phosphorylation 
 
Protein phosphorylation is the most common TAU post-translational modification in which a 
covalently bound phosphate group is added to an amino acid residue by a protein kinase. Even 
though TAU phosphorylation plays a key role in regulating the physiological functions of TAU at 
different neuronal locations, it has been reported that phosphorylation at the microtubule-binding 
domain (Figure 6), at the KXGS motifs, reduces its affinity for microtubules which results in the 
destabilization of the cytoskeleton of neurons (62).  
There is a total of 85 potential phosphorylation sites at three types of amino acids: serine 
(S), threonine (T) and tyrosine (Y), distributed along the TAU protein. The majority of these are 
located in the proline-rich domain of TAU, bordering the microtubule-binding domain (Figure 6). 
Approximately 45 of these 85 phosphorylation sites have been found in AD brain (62,63) 
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Figure 6. TAU phosphorylation sites identified in brains of AD patients. Diagrammatic representation of the most common 
TAU residues (Y in orange; S in purple and T in blue) shown to be phosphorylated in the AD brain. The kinases responsible 
for the respective phosphorylations are also indicated (when the information was available). The KXGS motifs are indicated 
*259-QIGS-262, **290-QCGS-293, ***321- QCGE-324, and ****353-QIGS-356. (taken  from (64)) 
 
For instance, phosphorylation at residues Ser262 (65), Ser356 and Thr231 (66) can 
dramatically reduce the ability of TAU to bind to microtubules, triggering its detachment (67).  
 The normal level of TAU phosphorylation is a result of dynamic regulation of TAU kinases and 
TAU phosphatases. More than 20 protein kinases in total can phosphorylate TAU proteins (68). Most 
of the kinases involved in TAU phosphorylation are part of the proline-directed protein kinases 
(PDPK), which include mitogen-activated protein kinase (MAPK), glycogen-synthase kinase-3β (GSK-
3β), TAU-tubulin kinase, cyclin-dependent kinases including CDC2 and CDK5 and stress-activated 
kinases (SAP kinases). Another group named non-PDPK or NPDPK comprises microtubule-affinity 
regulating kinase (MARK), Ca2+/calmodulin-dependent protein kinase II (CaMPKII), cyclic-AMP-
dependent kinase (PKA), casein kinase II and protein kinase C (PKC) (69). Among these kinases, 
glycogen synthase kinase-3β (GSK-3β), an isoform of GSK-3, is among the most implicated in the 
abnormal hyperphosphorylation of TAU in AD brains (70) and has been associated with PHF-TAU 
formation, neurite retraction, and neuronal death as well as a decline in cognitive performance.   
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Table 1. Phosphorylation sites of TAU in the Alzheimer’s Disease and the site-specificity of kinases (64,71) N.D., Not 
Defined. 
Human TAU 
residues 
Kinases 
Y18 FYN; SYK  
S46 GSK-3β; CK1; MAPK; ERK1/2; p38; SAPK2; SAPK3 
S68 N.D 
T69 GSK-3; ERK; p38 
T71 AMPK  
S113 CK1 
T123 CHK1; PSK1/TAOK2 
T153 GSK-3; CDK5; ERK; SAPK1γ; SAPK2; SAPK3; SAPK4; LRRK2 
T175 GSK-3β; JNK; ERK2; p38; SAPK1 γ; SAPK2; SAPK3; LRRK2; PSK2/TAOK1  
T181 GSK-3β; CDK5; JNK1; JNK2; JNK3; ERK2; p38; DYRK1A; SAPK1 γ; SAPK2; SAPK3; 
SAPK4; LRRK2  
S184 GSK-3β; CK1; SAPK2; SAPK3; PSK1/TAOK2; PSK2/TAOK1  
S185 p38; PSK1/TAOK2; PSK2/TAOK1 
S191 CHK1; PSK1/TAOK2; PSK2/TAOK1  
Y197 MET 
S198 GSK-3β; PKA; CK1; TTBK1; PSK1/TAOK2 
S199 GSK-3; PKA; CDK5; CK2; MAPK; JNK1; JNK2; JNK3; ERK2; TTBK1 DYRK1A; SAPK4; 
S202 GSK-3; PKA; CDK5; MAPK; JNK1; JNK2; JNK3; ERK2; p38; TTBK1; DYRK1A; SAPK1 
γ; SAPK2; SAPK3; SAPK4 
T205 GSK-3β; PKA; CDK5; JNK1; JNK2; JNK3; ERK2; p38; DYRK1A; SAPK1γ; SAPK2; 
SAPK3; SAPK4; LRRK2; PSK1/TAOK2; PSK2/TAOK1 
S208 CK1δ; CHK1; TTBK1; TTBK2; AMPK  
S210 GSK-3; PKA; CK1; LRRK2 
T212 GSK-3; PKA; CaMK-II; CDK5; CK1; JNK1; JNK2; JNK3; ERK2; p38; DYRK1A; SAPK1γ; 
SAPK2; SAPK3; SAPK4; LRRK2; p70S6K; PSK1/TAOK2 
S214 GSK-3β; PKA; PKB; PKC; PKN; CaMK-II; CDK2; CDK5; CK1; CHK1; CHK2; p38; 
SAPK1γ; SAPK2; SAPK3; SAPK4; AMPK; MSK1; p70S6K; PSK1/TAOK2; 
PSK2/TAOK1; RSK1/2; SGK1; SRPK2 
T217 GSK-3β; PKA; CaMK-II; CDK5; JNK1; JNK2; JNK3; ERK2; p38; DYRK1A; SAPK4; 
LRRK2 
T231 GSK-3; PKA; CDK5; JNK; ERK2; p38; DYRK1A; SAPK1γ; SAPK3; SAPK4; AMPK; 
LRRK2; PSK1/TAOK2; PSK2/TAOK1 
S235 GSK-3; PKA; CDK5; MAPK; JNK2; ERK2; p38; SAPK1γ; SAPK2; SAPK3; SAPK4; PhK; 
AMPK  
S237 GSK-3; CK1; PhK; LRRK2; PSK1/TAOK2; PSK2/TAOK1 CK1; PSK2/TAOK1 
S238 CK1; PSK2/TAOK1 
S258 GSK-3β; PKA; PKC; PKN; CK1δ; CHK1; AMPK; LRRK2; PSK1/TAOK2; PSK2/TAOK1 
S262 GSK-3; PKA; PKC; CaMK-II; CK1δ; CHK1; CHK2; MARK; PhK; AMPK; BRSK; LRRK2; 
MSK1; p70S6K; PSK1/TAOK2; PSK2/TAOK1; ROCK 
S289 GSK-3β; CK1δ; CHK1; CHK2; AMPK; PSK1/TAOK2; PSK2/TAOK1 
S356 GSK-3; PKA; CaMK-II; CK1δ; JNK; MARK; ERK; CHK1; p38; SAPK1γ; SAPK2; SAPK3; 
SAPK4; PhK; AMPK; LRRK2; PSK1/TAOK2; PSK2/TAOK1 
Y394 c-Abl; LRRK2  
S396 GSK-3; CDK5; CK1; CK2; MAPK; JNK1; JNK2; JNK3; ERK2; p38; DYRK1A; SAPK1γ; 
SAPK2; SAPK3; SAPK4 
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Human TAU 
residues 
Kinases 
S400 GSK-3β; CK2; CHK1; DYRK1A; AMPK; PSK1/TAOK2; PSK2/TAOK1 
T403 GSK-3β; CHK2; AMPK; LRRK2; PSK1/TAOK2; PSK2/TAOK1 
S404 GSK-3; PKA; CaMK-II; CDK5; CK1; CK2; MAPK; JNK1; JNK2; JNK3; ERK2; p38; 
DYRK1A; SAPK4 
S409 GSK-3β; PKA; CaMK-II; CHK1; CHK2; p38; SAPK3; SAPK4; PSK1/TAOK2; 
PSK2/TAOK1; ROCK 
S412 GSK-3; PKA; CK1; CK2; PSK2/TAOK1 
S413 GSK-3β; PKA; CK1; CK2; PSK1/TAOK2; PSK2/TAOK1  
T414 GSK-3β; PKA; CK1δ; CK2; CHK1; PSK1/TAOK2; PSK2/TAOK1 
S416 GSK-3; PKA; CaMK-II; CK1; CK2**; PSK1/TAOK2; PSK2/TAOK1 
S422 GSK-3β; PKA; CaMK-II; MAPK; JNK1; JNK2; JNK3; ERK2; p38; TTBK1; DYRK1A; 
SAPK4; 
T427 PSK1/TAOK2; PSK2/TAOK1  
S433 CK1δ; CHK2; PSK1/TAOK2; PSK2/TAOK1 
S435 PKA; CK1δ; CHK2; LRRK2; PSK1/TAOK2; PSK2/TAOK1 S 
 
Regarding protein phosphatases (PP), there are four major PPs associated with TAU 
phosphorylation, including PP1, PP2A, PP2B (calcineurin) and PP5 (60,72). It has been found that 
PP2A is by far the most important and major TAU phosphatase, as it has been demonstrated to be 
the most effective in dephosphorylating hyperphosphorylated TAU isolated from AD brains (73).  
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1.3.4. Physiological and Pathological role of TAU phosphorylation 
 
Phosphorylation can modulate the properties of TAU proteins and affect its cellular 
distribution in neurons, which regulates the different roles of TAU protein both in physiological and 
pathological conditions (54). The phosphorylation status of TAU is considered to change during 
development, with a relatively high degree of phosphorylation during the foetal phase followed by 
a steady decrease with age, possibly as a result of phosphatase activation (74).  
As mentioned above, in normal conditions, TAU phosphorylation at specific sites controls a 
variety of processes, but when in a hyperphosphorylated state, it affects microtubule assembly and 
polymerization (65). As the affinity to microtubules decreases other cellular processes like axonal 
transport are affected (75).  
TAU is present preferentially in axons, but it can appear in several cell compartments. 
Depending on its location the levels of TAU phosphorylation may vary, thus contributing to TAU 
trafficking and cell sorting (nuclear, axonal or somatodendritic) (76). The regulation of neurite 
outgrowth and neuronal polarization can also be controlled by phosphorylation (77). It is also 
noticeable that TAU phosphorylation might be developmentally regulated since it is heavily 
phosphorylated in foetal tissues and tends to decrease with age due to phosphatases activation (74).  
Under pathological conditions, TAU is delocalized from the axons to the somatodendritic 
compartment of neurons, where it tends to aggregate in a hyperphosphorylated state into tangles 
of paired helical filaments (PHF) and straight filaments forming neurofibrillary tangles. 
Hyperphosphorylation is defined as a high level of phosphorylation on epitopes localized at the C-
terminus and half-N-terminus of the TAU protein, outside the microtubule-binding domain. This 
abnormal phosphorylation is an early event of neurodegeneration and it becomes more severe with 
the development of the disease, affecting its physiological role (78).  
In the AD brain, TAU is approximately three to four times more phosphorylated than the 
normal adult brain TAU (79). The aggregation of this hyperphosphorylated TAU may block the 
intracellular trafficking of the neurotrophins and other functional proteins, and contribute to a 
decline or even loss of axonal transport in the neurons (80).  
Hyperphosphorylated TAU may also block intracellular trafficking in the neurons, affect cell 
morphology and cell growth, and promote cell cycle reentry. These changes may eventually lead to 
neuronal death (81). 
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1.3.5. TAU phosphorylation as a Predictive AD Biomarker  
 
TAU hyperphosphorylation appear to be useful as diagnostic markers, given the correlation 
with relatively early events in AD development, forming the pre-tangle PHF and mature NFTs.  
During this preclinical period, there is a gradual loss of axons and neurons, and the first 
symptoms start to appear (82). At this stage, patients do not fulfil the criteria for dementia and may 
be diagnosed with Mild Cognitive Impairment (MCI). People with MCI have the early neuropathology 
of dementia, particularly Alzheimer’s disease, but do not meet the clinical criteria. These individuals 
are more likely to develop clinical AD at a much higher rate than normal elderly people 
(approximately 15% each year) (83,84). For this reason, MCI has been considered as an early stage 
of Alzheimer’s disease and other forms of dementia, being, in some cases, the transition phase 
between healthy cognitive ageing and dementia (Figure 7). However, some individuals with MCI 
seem to remain stable or even return to normal cognition over time (85). 
 
 
 
 
Figure 7. The spectrum of cognitive impairment (CDR - Clinical Dementia Rating scale); Adapted from (86) 
 
It was reported that pTAU levels are increased in MCI converters (87) and that the specificity 
of pTAU to differentiate from other dementias is higher than that for total TAU reaching more than 
80%. CSF levels of phosphorylated TAU seem to reflect both the phosphorylation state of TAU and 
the formation of neurofibrillary tangles in the brain.  
The most studied phospho-epitopes in CSF are TAUpThr181 and TAUpThr231, which are the 
most reliable predictors of the decline from MCI to AD.  
Although both forms show similar sensitivities and specificities for AD, TAUpThr181 is more 
commonly used than TAUpThr231 (88,89). High CSF TAUpThr181 has also been associated with a 
fast progression from MCI to AD (90) and with a rapid cognitive decline in AD (91). The majority of 
studies in patients with AD evaluated the levels of TAUpThr181, although the levels of TAUpThr231 
have been reported to correlate better with post-mortem tangle load than do pTAU181 levels 
(87,92). Also, TAUpThr231 appears early in AD while TAUpThr181 occurs later (87,93).  
Phosphorylation at threonine 231 has been shown to be specific for AD. Thr231 is present in 
pre-tangles and precedes tau oligomerization and the assembly of paired helical filaments in the 
human brain. The TAU Thr231 residue is localized in the projection domain of TAU protein thus 
Dementia 
CDR = 
Normal MCI 
0 3 2 1 0.5 
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decreasing the interconnection between microtubules and other cytoskeletal components, such as 
actin (93). Thr231-phosphorylated TAU undergoes conformational changes that reduce the affinity 
of the protein for microtubules and it promotes the phosphorylation of other TAU residues (Ser199, 
Ser396, Ser400 and Ser404), causing TAU hyperphosphorylation and loss of function.  
Buerger et al, while analysing frontal cortex homogenates and CSF samples of AD patients 
found significant correlations between CSF TAUpThr231 concentrations and scores of NFTs in all 
neocortical regions studied, indicating that CSF TAUpThr231 may serve as a surrogate biomarker of 
neurofibrillary pathology in Alzheimer’s (94). Several other studies have shown TAUpThr231 levels 
to be elevated in AD compared with control subjects (95). It has also been shown to help to 
differentiate AD from other closely associated diseases, such as frontotemporal dementia, vascular 
dementia and dementia with Lewy Bodies (88).  
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2. Objectives of the study 
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2. Objectives 
 
Alzheimer Disease (AD) is a severe age-associated disease affecting millions of people 
worldwide (2). The identification of the disease has some limitations, and in some cases, the final 
confirmation arrives only after the patient’s death (33). Currently, AD diagnosis is based on a 
combination of several medical tools and can only detect the disease in a late and already 
symptomatic state. 
The development of differential biomarkers that are precise indicators of the pathogenic 
processes of AD is extremely important to detect the preclinical stages of AD, permitting early 
diagnosis, to monitor the progression of neurodegenerative diseases, to evaluate the responses to 
therapies and stratify the diseases in their different subtypes (41). There is an urgent need for a 
simple screening procedure that can identify AD patients in a differentiated, inexpensive and non-
invasive manner. Blood would be the ideal fluid to access biomarkers because it circulates through 
all the organs, but other peripheral fluids such as CSF also contain secreted proteins and may reflect 
changes in the state of the disease (33).  
The microtubule-associated TAU protein is the major component of intraneuronal NFTs, a 
hallmark of AD. TAU is released only upon axonal degradation and neuronal death, making it 
detectable in peripheral bodily fluids (47). Phosphorylation at threonine 231 has been shown to be 
specific for AD and to precede assembly of paired helical filaments in the human brain. 
Thus the specific aims of this dissertation are to:  
 
 Determine the function Thr231 phosphorylation and its contribution to TAU localization in 
SH-SY5Y neuroblastoma cells 
 To identify TAUpThr231 in CSF and blood  
 To explore the potential of pTAU231 levels in the CSF as a biomarker  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Materials and methods 
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3. Materials and methods 
3.1. Antibodies 
 
The following primary antibodies were used: mouse monoclonal anti-TAU antibody 
(Millipore, clone TAU-5, cat. # MAB361) to detect all phosphorylated and non-phosphorylated 
isoforms of TAU; rabbit monoclonal anti-TAU TAUpThr231 (Invitrogen/Life Technologies, clone 
1H6L6, cat. # 701056), which specifically recognizes phosphorylated TAU at Thr231; Anti-
Microtubule Associated Protein 2 Mouse mAb (Calbiochem, cat. #442695); Mouse Anti β-Tubulin 
(Invitrogen, cat. #32-2600); pTAU (Ser262), rabbit polyclonal antibody (Santa Cruz Biotechnology, 
cat. #sc-101813); Anti-TAU (phosphor S396) antibody (abcam, cat. #ab109390); rabbit Anti-Actin 
Polyclonal Antibody (Stressgen Bioreagents, cat. #CSA-400). 
 
Table 2. Summary of the antibodies used to detect target proteins and specific dilutions used for the different assays. 
The specific dilutions used for the different assays are also indicated. IB: Immunoblotting; IP: immunoprecipitation; IF: 
immunofluorescence 
Antibody  Target Protein  Reactivity Dilution  Expected bands 
site (kDa)  
Phospho TAU 
pThr 231 
(Thermo) 
pTAU at Thr 231  Rabbit IB dilution: 1:250 
IF dillution: 1:500 
⋍55 
TAU-5  
(Millipore) 
total TAU  Mouse IB dilution: 1:500  
IF dilution: 1:200 
IP dilution: 1:100  
46-68  
MAP2 
(Calbiochem) 
MAP2 Mouse IB dilution: 1:2000  
IF dilution: 1:1000 
⋍70 
β-Tubulin 
(Invitrogen) 
β-Tubulin Mouse IB dillution: 1:2000 ⋍50 
pTAU Ser262 
(Santa Cruz) 
pTAU at Ser 262 Rabbit 
  
IB dillution: 1:500 46-68 
pTAU Ser396 
(abcam) 
pTAU at Ser 396 Rabbit IB dillution: 1:5000 79 
Anti-Actin 
(Stressgen) 
total Actin  Rabbit IB dillution: 1:1000 ⋍43 
 
Horseradish peroxidase-conjugated anti-mouse (1:5000) and anti-rabbit (1:5000) IgGs were 
used as secondary antibodies (Amersham Pharmacia) for immunoblotting. For 
immunocytochemistry Texas Red-X goat anti-rabbit IgG (H+L) (Molecular Probes) and Alexa Fluor 
488 goat anti-mouse IgG (H+L) (Life Technologies) was used as secondary antibodies (Table 2). 
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3.2. Cell Culture  
3.2.1. Culture, growth and maintenance of SH-SY5Y cell line 
 
In neurosciences, the use of mammalian neurons derived from embryonic the CNS tissue is 
very limited mainly because once these cells are terminally differentiated into mature neurons, they 
can no longer be propagated. To overcome this limitation transformed neuron-like cell lines are 
commonly used. Among them, there is a very popular and well characterized one, the SH-SY5Y 
neuroblastoma cell line (ATCC® CRL-2266™).(96) 
The SH-SY5Y cell line was originally derived from a metastatic bone tumour biopsy, and a 
subline of the parental line SK-N-SH, which were subcloned three times: first to SH-SY, them to SH-
SY5, and finally to SH-SY5Y.(96) 
In order to archive the objectives proposed for the present study, SH-SY5Y neuroblastoma 
cell line was chosen for the reasons described above, and because this cell line is a human cell line 
that can be easily differentiated into a more mature neuronal-like phenotype.  
Human SH-SY5Y neuroblastoma cells (ATCC® CRL-2266™) were grown and maintained in 
Minimal Essential Medium (MEM)/F12 (1:1) medium supplemented with 10% fetal bovine serum 
(FBS), 0.5 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. Cultures were 
maintained in a humidified chamber at 37°C under 5% CO2 (96). Cells were subcultured whenever 
80-90% confluence was reached. The procedures are in routine use in the laboratory. 
 
3.2.2. Cell Differentiation 
 
Differentiation of SH-SY5Y cells is relatively easy to achieve by manipulation of the culture 
medium. There are many reagents\compounds that can be added to culture medium in order to 
differentiate SH-SY5Y cells, but Retinoic Acid (RA) is the most commonly used (96–98). 
Cells were allowed to adapt for 24 hrs (day -1) and were then subjected to differentiation. 
Differentiation of SH-SY5Y cells was achieved by adding all-trans-retinoic acid (RA) to the culture 
medium, at a concentration of 10 µM and FBS at 1%. This culture medium was replaced every 48 
hours until the time of 5 days was reached. 
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3.2.3. Aβ Treatment 
 
Aβ42 peptide (GenicBio Synthetic Peptide cat. #A-42-T-1)) was reconstituted in sterilized 
H2O miliQ (1mM stock) and aggregated in phosphate-buffered saline (PBS, pH 7.4), for 48 h at 37°C 
(100 μM aggregated stock). In order to mimic AD, the cells were exposed to crescent concentrations 
(0, 2, 10 and 20 μM) of aggregated Aβ with the corresponding medium serum free for 3h at 37°C 
(99).  
 
3.2.4. Sample Collection 
 
After the appropriate treatments, cell lysates for immunodetection were washed in ice-cold 
PBS and then collected from each well by pipetting up and down with RIPA lysis buffer (Sigma, cat. 
#R0278) containing a protease inhibitor cocktail (cOmplete, EDTA-free, Roche, cat. #11873580001). 
The lysates were sonicated twice during 5 seconds and stored at -20ºC. Protein determination 
content was perform using BCA assay (see Section 3.4) and normalized protein samples were 
electrophoretically separated by 5-20% gradient SDS-PAGE gels followed by immunoblotting for the 
specific protein. Detection was carried out using a chemiluminescence method. The resulting bands 
were quantified by ChemiDoc Touch Imageing (see Section 3.7). 
 The adherent cells seeded on coverslips for immunocytochemistry were fixed in 
Paraformaldehyde 4% (PFA) and subsequently processed for staining as described in section 3.5.  
 
3.3. CSF Sample Collection and Handling  
 
 The CSF samples were obtained by means of lumbar puncture in the hospital of Santa Maria 
da Feira, and aliquots were stored at −80°C until analysis. Then were centrifuged at 3000 rpm for 
5min and stored in -80ºC until biochemical assays. Estimation of CSF levels of Aβ42, total TAU and 
pTAU phosphorylated at threonine-231 and threonine-181 were measured by ELISA, using 
commercially available kits (Human TAU [pT231] PhosphoELISA™ Kit, Invitrogen; INNOTEST 
PHOSPHO-TAU [181P] Antigen, Innogenetics; INNOTEST hTAU-Ag, Innogenetics; INNOTEST β-
amyloid [1-42], Innogenetics). 
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3.4. BCA Protein Quantification Assay  
 
Protein quantification of all samples was performed by colourimetric biocinchoninic acid 
(BCA) protein assay, using Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific, cat. #23225). This 
assay depends on the capability of protein to reduce Cu2+ to Cu+ in an alkaline medium (the biuret 
reaction), which produces a purple-coloured reaction formed by chelation of two molecules of BCA 
with one cuprous ion. This water-soluble complex exhibits a strong absorbance at 562 nm.  
Samples of 5 μl of SH-SY5Y lysates, plasma, serum or CSF were homogenised with buffers 
(RIPA), directly in the wells (Table 3). Both standards and samples were incubated with 200 μl of 
working reagent which is prepared with 50 parts of reagent A to 1 part of reagent B. The plate was 
incubated at 37ºC for 30 min and the absorbance of BCA assay was immediately measured at 562 
nm using TECAN Infinite M200.  
 
Table 3. Standards used in BCA protein assay method. BSA: Bovine serum albumin (2 mg/ml); WR, Working Reagent 
 
Standards BSA (µL) Buffer (µL)  Protein mass (µg) 
P0 - 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
 
3.5. Immunocytochemistry 
 
Immunocytochemistry techniques allow for the detection and localization of antigens in cells 
and tissues via the use of specific antibodies labelled with fluorochromes (in the case of 
immunofluorescence). The principle of fluorescence is based on the fact that the electrons are 
arranged at energetic levels around the atom. Whenever they absorb energy, each electron rises to 
a higher, less stable energy level. This excited state does not last very long and soon afterwards the 
electron loses energy in the form of heat and the rest in the form of a photon. There is a range of 
wavelengths that can excite the electrons of a fluorophore with an optimal peak of excitation for 
which more fluorescence is produced. The light produced by fluorophores is also represented by a 
range of values with an optimum emission peak (100). 
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This technique involves several and crucial steps in order to obtain good final preparations. 
First samples are prepared by fixing with a fixation agent, this agent helps to stabilize and preserve 
cells as close to life-like as possible by binding to reactive groups on proteins and lipids and holding 
them in the same position as if the cells were still alive. The second step is the permeabilization of 
the cells achieved by the addition of detergents, which can solubilize membranes without destroying 
the protein-protein interactions. After this cells are blocked, incubated with the chosen antibody and 
corresponding fluorescent secondary antibody and mounted in a media with anti-fading and anti-
photobleaching properties. Finally, the preparation can be visualized through a microscope, and 
images analysed (100).  
SH-SY5Y cells were plated onto coverslips at a confluency of approximately 50%. The cells’ 
differentiation was induced with retinoic acid. The cells were fixed with 4% paraformaldehyde for 10 
minutes, permeabilized with 0.2% Triton X-100 for 10 minutes and blocked with PBS 5%BSA for 1 
hour at room temperature. Subsequently, cells were immunolabelled with specific antibodies. In 
order to distinguish between TAUpThr231 and TAU-5, the cells were either labelled with anti-
TAUpThr231 monoclonal antibody (Thermo) 1:500 and anti-TAU-5 antibody, mouse (Millipore) at 
1:200 in PBS 3% BSA or with anti-TAUpThr231 monoclonal antibody (Thermo) 1:500 and incubated 
for 3 hours or overnight at room temperature. Primary antibody complexes were visualized using 
Texas Red Goat anti-Rabbit IgG (H+L) (Molecular Probes) at a dilution of 1:400 and Alexa Fluor® 488 
Goat anti-Mouse IgG (H+L) (Life Technologies) at a dilution of 1:300 in 3% BSA in PBS for 1h at room 
temperature. Coverslips were then mounted onto a microscope glass slides with VECTASHIELD® 
Mounting Medium for fluorescence, an antifading reagent containing DAPI for nucleic acid labelling 
(Vectashield, Vector Laboratories) and visualized using an Olympus IX81 fluorescence microscope. 
Co-localization studies of TAU-5 and TAUpThr231 were carried out by immunofluorescence analysis. 
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3.6. SDS - Polyacrylamide Gel Electrophoresis  
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is an analytical 
technique used to separate proteins from a mixture, based on protein molecular weight and charge.  
The principle of this electrophoresis method relies on the capacity for proteins to migrate through 
gel pores when placed under an electrical field. The gel percentage and size depend on the molecular 
weight of the proteins to be separated. As different proteins contain different charges what would 
interfere with the running, SDS is applied to confer a negative charge to all proteins. One molecule 
of SDS can bind to two amino acid residues. Therefore, all proteins can migrate from negative to 
positive anode. SDS is also used in combination with a reducing agent (β-mercaptoethanol) and heat 
to dissociate proteins before they are loaded on the gel. These reagents cleave disulphide bonds to 
disrupt tertiary and quaternary protein structures, ensuring protein linearization and equal protein 
migration in the gel, independently of the three-dimensional structure.  
Samples were subjected to 5-20% gradient SDS-PAGE in a Hoefer electrophoresis system. 
Gels are composed of 2 phases, the non-restrictive large pore called stacking gel and resolving gel 
with a linear progression of acrylamide concentrations from top to bottom, resulting in a wider 
separation range. The gradient gel was prepared and allowed to polymerize for 1 h at room 
temperature. Subsequently, the stacking gel solution was prepared and loaded on the top of gradient 
gel. A comb was inserted and the gel and left to polymerize for 1 hour at room temperature.  
In parallel, samples were prepared by adding to the protein sample solution ¼ volume of 4X 
LB (Loading Buffer), boiled for 5 minutes. The combs were removed and the gels wells filled with 
Tris-Glycine running buffer. The samples were carefully loaded into the wells and electrophoretically 
separated using a 90 mA electric current for 3-4 hours. Molecular weight markers (Precision Plus 
ProteinTM Dual Color Standards, Bio-Rad, cat. #1610374) were also loaded and resolved side-by-side 
with the samples. 
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3.7. Western Blot 
 
 Western blotting is the technique used for detection of specific proteins in complex samples 
like cell lysates, cell culture supernatants or body fluids. In this technique, the proteins that were 
electrophoretically separated by SDS-PAGE can be transferred to a solid membrane (nitrocellulose 
membranes, for instance), by an electrophoretic field while keeping their positions. This is a fast and 
efficient procedure and preserves the high-resolution separation of proteins by SDS-PAGE. Once in 
the membrane, proteins are suitable for detection by total protein staining or labelling the proteins 
of interest with specific antibodies (101).  
After SDS-PAGE gels proteins were electrophoretic transferred to nitrocellulose membranes 
in a wet system for 18h and at 200 mA. The transfer was further confirmed using Ponceau staining 
solution, which is a red stain dissolved in an acidic solution. Ponceau S binds to protein positive amino 
acids and to non-polar protein regions in a non-covalent form. The membrane was hydrated with a 
Tris-buffered saline solution (TBS) during 10 min with agitation and, then, Ponceau staining solution 
was applied during 5 min with agitation. After this incubation, the solution was removed and the 
membrane was washed with deionized H2O to remove the excess of ponceau solution (101). 
For immunodetection, after total Ponceau removal, membranes were blocked in 5% BSA  in 
1x TBS-T (0.5% Tween-20), at RT during 4 hours, to inhibit possible non-specific binding sites of the 
primary antibody. Membranes were incubated with primary antibody in 3% BSA extract solution for 
4 hours with agitation at room temperature plus overnight at 4°C. Membranes were washed with 
TBS-T six times for ten minutes and then incubated with the appropriate secondary antibodies 
coupled to horse radish peroxidase (HRP) for 2h at room temperature. The membranes were washed 
five times for ten minutes each with 1x TBS-T. 
Protein bands were detected using the chemiluminescence reagent Amersham ECL Select 
Western Blotting Detection Reagent (GE Healthcare Life Sciences). Enhanced chemiluminescence 
(ECL) reagent is based on luminol substrate oxidation by HRP, generating chemiluminescence at 425 
nm. The emitted light is directly proportional to the amount of protein. The membranes were 
incubated for 5 min with the working mixture of the chemiluminescent detection reagent, at room 
temperature. Images were exposed between 1 min and 30 min and the resulting image was observed 
in ChemiDoc Imageing System. 
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3.8. Enzyme Linked Immuno Sorbent Assay 
 
The Enzyme Linked Immuno Sorbent Assay (ELISA) method is a potent method for detecting 
and quantifying a specific protein in a complex mixture as it allows for analysing protein samples 
immobilized on a microplate using specific antibodies.  
A solid-phase sandwich ELISA (Human TAU [pT231] PhosphoELISA™ Kit, cat. # KHB8051, 
Invitrogen) assay was used to detect TAU phosphorylated at Thr231 (PTAU231). The ELISA sandwich 
is used for more complex protein samples since only the antigen of interest is immobilized on the 
antibodies, the capture antibody and the detection antibody. All reagents used were supplied in the 
kit including the “standards dilution buffer”. Wash buffer was prepared by diluting the supplied 
concentrate 1:25 with purified water.  
Standards were prepared by diluting the supplied standard with “standard dilution buffer” 
as specified on labelling to 100 U/mL. The standard curve was constructed by 8 double down 
dilutions starting at a content of 50 U/ml down to 1.56 U/ml, plus a 0 point. The calibrator used for 
the assay was a recombinant Hu TAU-441 expressed in E. coli and SMCC conjugated to phospho-
peptide T231.  
A specific TAU monoclonal antibody was coated onto the wells of a 96-well plate. During the 
first incubation, 100 μL of standards of known TAU [pT231] content and samples were added to each 
well and the TAU antigen bind to the immobilized (capture) antibody. The ELISA plate was covered 
and incubated for 2 hours at room temperature on a shaker. After washing, a rabbit antibody specific 
for TAUpThr231 was added to the wells. The plate was incubated as above for 1 hour and thereafter 
washed 4 times. During the second incubation, this antibody served as a detection antibody by 
binding to the immobilized TAU protein. After washing, we added a horseradish peroxidase labelled 
anti-rabbit IgG that binds to the detection antibody, and the plate was incubated for 30 minutes at 
room temperature. After a third incubation and washing to remove all the unbound enzyme, a 
stabilized chromogen (TMB) was added, which binds to the enzyme to produce colour. The 
uncovered plate was incubated at room temperature in the dark for 30 minutes. The reaction was 
completed by the addition of a provided “stop” solution, and the plate was then read at 450 nm in a 
Tecan microplate reader. The intensity of this coloured product is directly proportional to the 
concentration of TAU [pT231] present in the original specimen and the optical density can be read 
on a standard microplate reader. 
Phospho-TAU (181P), Total TAU and Amyloid-β (Aβ42) levels were measured using 
commercially available ELISA microplate assay (Innotest®, Innogenetics, Ghent, Belgium). 
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3.9. Albumin Depletion  
3.9.1 Albumin/IgG using ProteoSeek columns 
 
Plasma samples for immunoblotting were stripped of Albumin/IgG using ProteoSeek 
columns (IgG removal kit, Thermo Sci, cat. #89875). This is a high capacity kit that uses an 
immobilized Cibacron Blue dye agarose resin capable of binding with a variety of species-specific 
albumins. This is placed in the Pierce Spin Columns and by low-speed centrifugation, the albumin 
binds to the resin making possible its removal from the samples. 
 
3.9.2 Immunoprecipitation 
 
Immunoprecipitation (IP) is a technique in which a target protein, antigen or protein complex 
is precipitated from a solution using a specific antibody. It is widely used to estimate molecular 
weight, identity, quantity and expression levels of a protein of interest and to study protein-protein 
interactions. 
 The magnetic DynaBeads are the solid support used in our immunoprecipitation approach. 
The immunecomplexes attached to DynaBeads are easily removed from the supernatant by 
magnetic separation. The pure precipitate can then be eluted from the beads and analyzed by 
western blotting or mass spectrometry. In this specific case, DynaBeads are coupled to protein G 
that has different affinity to Ig’s of different species. 
After BCA protein quantification (see Section 3.4), normalized samples were pre-cleared 
with 15µL Dynabeads® Protein G (Thermo Sci, cat. #10004), for 1 hour at 4ºC with rotation. 
DynaBeads Protein G was previously washed twice with 3% BSA/1x PBS. Subsequently, the 
supernatant was transferred to a new microtube that contained 40 µL DynaBeads conjugated with 
the specific primary antibodies (TAU Total, dilution 1:100) and incubated overnight at 4ºC with 
rotation. Further, the supernatant was transferred to a new microtube and the DynaBeads washed 
three times with 3 % BSA/1x PBS and three times with 1x PBS (10 minutes each, at 4ºC with agitation). 
Finally, DynaBeads were re-suspended in 100 µL of 1x Loading Buffer and boiled at 70ºC for 10 min. 
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3.10. Quantification and Statistical analysis 
 
Image Lab™ Software 6.0 (Bio-Rad) was used to quantify band intensity and correlate it to 
protein levels. The Shapiro-Wilk normality test was used to assess the normality of distribution of 
investigated parameters. Difference between groups was established using ANOVA. The unpaired t-
test was used to compare means and correlation analyses were performed using Pearson's test.  The 
values P < 0.05 were considered statistically significant. Statistical analyses were performed using 
IBM SPSS Statistics V22.0. Plots were made using the GraphPad Prism version 7.00 for Windows, 
GraphPad Software (La Jolla, California, USA). 
Quantification of colocalization was performed using Image J (NIH) in individual frames after 
thresholding, and colocalization was calculated with the JACoP plugin of the same program in 
merged images.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Results 
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4. Results and discussion 
4.1 SH-SY5Y cells and PhosphoTAU231 
4.1.1 Aβ effects in TAU phosphorylation 
 
In order to mimic AD, aggregated Aβ42 peptide was added at increasing concentrations (2, 
10 and 20μM) for 3 hours to undifferentiated and differentiated SH-SY5Y cells, as explained in section 
3.2.1. Following this incubation period, the cell lysates were collected and further analysed by 
immunoblotting using TAU-5, TAUpThr231, β-Tubulin and Actin antibodies. β-Tubulin was used as 
differentiation control and Actin was used as loading control.  
When the SH-SY5Y cells undifferentiated and differentiated were incubated with increasing 
concentrations of aggregated Aβ42 for 3 hours, there seemed to be no significant changes in TAU 
levels with Aβ42  (Figure 8A), but it is significantly increased with differentiation (P=0.025). In the 
same experimental set, tubulin appears to be increasing with the differentiation (Figure 8A).  
 
(A) 
  Undifferentiated SH-SY5Y Differentiated SH-SY5Y Marker 
 [Aβ]μM                        0        2        10       20 0        2        10       20 kDa 
(I) TAU-5 
  50 
(II) TAUpThr231 
  50 
(III) β-Tubulin 
  50 
(IV) Actin 
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Undifferentiated Differentiated 
Figure 8. Effects of Abeta on TAU phosphorylation at Thr231 residue. Differentiated and undifferentiated SH-SY5Y were 
incubated for 3 hours with aggregated Aβ42 (2, 10 and 20 μM) A. Cells lysates were collected and protein levels of TAU-5 
(I) and TAUpThr231 (II) were analysed. β-Tubulin was used as a loading control (III) B. The expression levels of TAUpThr231 
(I) and TAU-5 (II) were measured. C. Quantification of TAU phosphorylation at Thr231 were normalized to Total TAU 
content. The undifferentiated control was set at 1 and the fold increase/decrease was calculated. All data represent means 
± SEM. Data were obtained from triplicate experiments. The relation between groups was calculated using the unpaired 
Student’s t-test, * P < 0.05 
 
Relative to the TAU phosphorylation, more specifically at the Thr231 residue the levels were 
very similar with the concentration of Aβ, but there was a significant increase in the phosphorylation 
in the differentiated cells when compared with the undifferentiated SH-SY5Y cells in the control 
(p=0,029). This may indicate that the phosphorylation of the Thr231 residue is not due to increasing 
Aβ but may be a relevant process associated with cell differentiation.  
In order to have a clearer idea of the phosphorylation pattern on this residue, following Aβ 
1-42 treatment the ratio of phosphorylated TAU protein (pTAU) versus total TAU protein (total TAU) 
was calculated (Figure. 8C). The analysis of this ratio revealed that TAU phosphorylation upon Aβ42 
treatment at Thr231 does not have significant differences when Aβ42 is added for 3 hours, but there 
is still a significant increase in the phosphorylation in the differentiated cells when compared with 
the undifferentiated SH-SY5Y cells in the control (p=0,049). 
To see if the tendency to increase phosphorylation when cells are differentiated is specific 
for this residue, we tested other TAU phosphorylation sites (Ser262, Ser369) as well as another 
microtubule-associated protein, MAP2. Total TAU and Tubulin were included as controls.  
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Figure 9. Differences in protein expression in undifferentiated and differentiated SH-SY5Y A. Cells lysates were collected 
and protein levels of phosphoTAU231, TAU-5, phosphoTAU262, phosphoTAU369, MAP2 and β-Tubulin were analysed by 
Western blot. B. The expression levels were measured. All data represent means ± SEM. Data were obtained from triplicate 
experiments. The relation between groups was calculated using the unpaired Student’s t-test, ** P < 0.01, *** P<0,001  
 
There were no apparent differences in phosphorylation levels at the TAU phosphorylation 
sites tested, apart from Thr231, which was significant (P < 0.001). Additionally, there was a tendency 
for MAP2 and TAU levels to increase with differentiation. Tubulin was significantly increased (P = 
0.002). 
 
4.1.2 Phospho TAU 231 localization  
 
Changes in the subcellular distribution and conformation of TAU during the progression of 
Tauopathies have been studied in an attempt to understand the process of neurofibrillary tangle 
(NFT) formation. 
To this end, SH-SY5Y neuroblastoma cells were differentiated with RA for five days into 
neuron-like cells displaying morphological and biochemical features of mature neurons, as described 
in the methods. Contrast-phase photographs were taken to visualize morphological differences in 
undifferentiated and differentiated cells (Figure 10).  
 
 
n.s n.s 
n.s 
n.s 
 ** 
*** 
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Undifferentiated 
 
Differentiated 
 
 
Figure 10. Differentiation of SH-SY5Y cell line, (Scale Bar = 100 μm).  
 
Undifferentiated SH - SY5Y cells tend to grow in clusters and may form clumps of rounded 
cells on top of one another. Differentiated SH - SY5Y cells do not cluster. The differentiated SH-SY5Y 
cells have an apparent neuronal morphology with more elongated phenotype and extensive neurite 
outgrowth, reminiscent of dendrites and/or axons.  
In this study, we examined the intracellular distribution of total TAU and TAUpThr231 in 
undifferentiated and RA-differentiated SH-SY5Y cells (Figure 11) by immunocytochemical staining 
using mouse monoclonal antibodies against TAU-5 and anti-TAU pT231, respectively.  
In both undifferentiated and differentiated SH-SY5Y cells, total TAU is mainly located in the 
cytosol (Figure 11). 
Undifferentiated neuroblastoma SH-SY5Y cells predominantly expressed pTAU231 proteins 
at the nucleus, while after RA-differentiation TAUpThr231 immunostaining was also found in the 
cytosol and along the neuritic processes (Figure 11). 
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(B)  
  
 
Figure 11. Total and TAUpThr231 protein distribution in undifferentiated and RA-differentiated SH-SY5Y cells. (A) Co-
immunostaining for TAUpThr231 (red staining) and TAU-5 (total TAU-green staining) showed no detectable overlap in the 
undifferentiated cells. TAUpThr231 localized mainly in the nucleus. TAU protein distributed along the cytosol of 
undifferentiated SH-SY5Y cells. RA treatment shifts the distribution of Total and Phosphorylated TAU protein into the 
neurites (B) Representative staining profiles. Left-undifferentiated cells, right-differentiated. Fluorescence intensity 
profiles represent the voxels through the white lines indicated in the merged image shown in A. (Scale Bar = 20 μm). 
 
In the undifferentiated SH-SY5Y cells most TAUpThr231 localized to the cell nuclei. Co-
immunostaining for TAUpThr231 and TAU revealed slight overlap in the cytosol. Induction of 
differentiation using RA resulted in neurite formation and a shift in TAU distribution from soma to 
neurites (Figure 11A). We found, as demonstrated in the fluorescence profile, that the level of 
phosphorylated TAU decreased in the nucleus (DAPI-positive organelle) after the differentiation 
treatment of SH-SY5Y with retinoic acid, and became detectable in the cytosol and along the 
processes (Figure 11B). Hence the blue trace (labels the nucleus) is sustained with RA exposure, 
whereas the red trace for TAUpThr231 drops, to similar values of those of the green trace for t-TAU. 
Of note, this analysis was carried out in non-apoptotic cells, as denoted by nucleus morphology (DAPI 
staining). This finding may suggest that the translocation of pTAU from the nucleus to the cytosol is 
part of the differentiation program.  
The co-localization of TAU and TAUpThr231 with DAPI was analysed to see their percentage 
of nuclei localization (Table 4). 
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Undifferentiated  Differentiated  
Table 4. Percentage of protein localized in the nuclei. Data is presented as mean±SD of a of minimum 20 analysed cells 
of each condition 
 
 TAU T231 
 Mean (SD) Mean (SD) 
Undifferentiated 31.21 (16.99) 54.88 (28.97) 
Differentiated 24.27 (10.19) 39.56 (25.7) 
 
There is a significant decrease in the percentage of TAUpThr231 localizing in the nuclei of 
differentiated cells when compared with undifferentiated cells (P=0.018). 
Finally, we analysed the percentage of co-localization among the previous proteins (Figure 
12). Colocalization coefficients of Manders (M1 and M2) represent the percentage of a protein 
colocalizing with the other. When both coefficients are equal to 100, there is a perfect co-
localization. In this case, M1 represents the percentage of TAUpThr231 that co-localizes with TAU 
and M2 represent the percentage of TAU that co-localizes with TAUpThr231. TAUpThr231 
colocalization with TAU significantly increased with differentiation (P=0.002).  
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Figure 12. Percentage of co-localization distribution of T231:TAU in undifferentiated and RA-differentiated SH-SY5Y cells. 
Data is presented as mean±SEM of a of minimum 20 analysed cells of each condition.*P<0,05, **P<0,005 
 
 
 
 
 
 
 
 
 
 
 
** 
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4.2. Optimizing TAUpThr231 detection in Human Samples 
 
The use of CSF biomarkers, despite being good predictors of AD, is hampered by a high 
degree of invasiveness, requires a lumbar puncture, has high costs, and availability is limited. 
Biomarkers based on standard blood tests represent several advantages. Results based on research 
would allow for efficient monitoring of disease processes in AD and could be used as a screening tool 
in primary health care. Thus this section addresses analysing human blood samples for putative AD 
biomarkers. 
Proteomic-based approaches are being sought with respect to blood-based diagnostics. 
However, the use of proteomics for efficient, accurate, and complete analysis of clinical samples 
poses a variety of technical challenges. The presence of higher abundance proteins in the plasma, 
such as Human serum albumin (HSA), may mask the detection of lower abundance proteins such as 
TAU, as it often accounts for greater than 60% of the total protein present in serum samples.  
A number of different strategies have proved efficient in selectively extract therapeutic 
proteins from this albumin reach plasma/serum samples. These approaches includes techniques, 
such as albumin depletion using plates or columns and immunoaffinity purification using antibodies. 
In our study, in order to remove Albumin/IgG from the plasma and serum samples, ProteoSeek 
columns were used. Protein content was determined by BCA protein assay Kit (Pierce, Rockford, IL, 
USA). Then the proteins in the samples were separated by SDS-page followed by Western Blot 
procedures. With the BCA method it was visible that the protein content diminished significantly 
after being subjected to the ProteoSeek columns but after the incubation with TAUpThr231 
antibody, we could not be sure that the band detected corresponded to TAUpThr231 or if it was still 
Albumin (data not shown). Also, this columns may result in the removal of other proteins other than 
albumin, and as the initial volume is only 10 μL and TAU in blood in in small quantity, this may not 
be the best solution. 
In a different approach, an immunoprecipitation with Dynabeads in plasma and serum 
samples was used to isolate total TAU-5 protein. The immunoprecipitates were then separated by 
SDS-page followed by immunoblotting using TAUpThr231 antibody. The interference of several 
blood abundant proteins was still extremely evident and we could not detect the TAUpThr231 band 
(data not shown). 
Given that one could not accurately detect TAUpThr231 by Western Blotting, we tried to 
determine the levels of TAUpThr231 in plasma, serum and CSF samples with a Human TAUpThr231 
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ELISA Kit. This kit did not detect significant levels in plasma nor serum but had positive results in CSF 
(Table 5). 
 
 
Table 5. Human TAUpThr231 ELISA Kit test results in several human fluids 
Sample Abs (562 nm)med Protein Content (μg) 
Serum 0,0893 1,57 
Plasma 0,0877 1,52 
CSF 0,1732 4,22 
 
Therefore, to determine how the degeneration of brain cells containing 
hyperphosphorylated TAU in AD is reflected in the CSF, TAU phosphorylated at Thr181 and Thr231, 
Total TAU and Aβ42 were quantified using several immunoassays using CSF samples of human 
patients, as described in section 3.9. A total of 50 samples were divided into 3 groups, according to 
their neurochemical and psychological diagnosis (the ELISAS for TAUpThr181, t-TAU and Aβ42 had 
been previously carried out, Henriques et al, personal communication).  
In the CSF samples, we observed that the levels of Aβ peptide were significantly decreased 
in the AD group when compared to the non-AD group (P<0.0001) (Figure 13A). In contrast, the levels 
of t-TAU protein significantly increased in patients with AD when compared with the non-AD group 
(P<0.0001) and with the amyloid pathology group (P<0.0001) (Figure 13B). TAUpThr181 is also 
increased in CSF samples of AD patients when compared to non-AD (P<0.0001) and positive Aβ 
samples (P<0.0001) (Figure 13C). TAUpThr231 did not have statistically significant changes (P=0.33) 
(Figure 13D). 
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Figure 13. Aβ, TAU and TAU phosphorylation levels in CSF samples. CSF samples of AD negative, Aβ positive and AD 
patients were assayed using specific ELISA kit for Aβ peptide (A), total TAU (B), TAUpThr181(C) and TAUpThr231 (D). The 
relation between groups was calculated using the unpaired Student’s t-test, **** P < 0.001 
 
In order to have a clear idea of the phosphorylation pattern on these residues, the ratio of 
phosphorylated TAU protein (pTAU) versus total TAU protein (total TAU) (Figure 14) was calculated.  
(B) (A) 
(C) (D) 
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Figure 14. Phospho TAU and TAU ratio. CSF levels of PTAU normalized against levels of total TAU (PTAU to t-TAU ratio).The 
ratio of the phospho TAU with the total TAU were calculated. The PTAU to t-TAU ratio in AD CSF was significantly lower 
than the other groups. The relation between groups was calculated using the unpaired Student’s t-test, ***P < 0,001; **P 
< 0,005; *P < 0,05. 
 
The analysis of this ratio revealed that both TAU phosphorylation in Thr181 (P = 0,002) and 
Thr231 (P < 0,001) exhibits a tendency to significantly decrease in AD positive patients compared 
with non-AD and patients with amyloid pathology. Moreover, TAUpThr231/t-TAU ratio levels 
seemed to improve diagnostic accuracy compared with TAUpThr181/t-TAU ratio levels in patients 
with AD. 
To evaluate the diagnosis significance to discriminate AD from non-AD individuals of both 
ratios, we did a ROC curve (Figure 15). The curves were constructed by computing the sensitivity and 
specificity of the ratios. If the area under the ROC curve is closer to 1, you have better test. Both 
ratios were considered to be "good" at discriminating between Alzheimer’s disease patients and non-
AD. We found that the diagnosis performed more accurately in T231 ratio (area under the curve = 
0.89, SD=0.060, 95% CI: 0.73 to 0.97) compared to T181 ratio (area under the curve = 0.86, SD=0.063, 
95% CI: 0.70 to 0.96). These differences however were not statistically different (P = 0.777). 
 
 
 
** 
*** 
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Figure 15. ROC Curve analysis of the sensitivity and specificity of both phosphoTAU/TAU ratios as discriminators of AD 
and Non-AD individuals 
 
Other relevant characteristics of the study group are summarized in table 4 to better analyse 
the relationship between some relevant variables analysed. 
 
Table 6. Characteristics of the study population. P-Values calculated with ANOVA. 
Variable 
Non-AD 
(N=20) 
Amyloid Pathology 
(N=18) 
Probable AD 
(N=12) 
 
P Value 
Age (years) 64.4 (56-77) 71.1 (46-85) 70.1 (57-85) 0.06 
Female, No. (%) 55 67 50 0.43 
ApoE ε4 genotype (0/1/2), No 19/1/0 11/6/1 7/2/3 0.11 
CSF Aβ42, mean (SD), pg/mL 704.5 (155.02) 327.44 (149.64) 339.58 (79.80) <0.001 
CSF TAU, mean (SD), pg/mL 214.50 (74.58) 275.94 (149.60) 887.25 (259.65) <0.001 
CSF TAUpThr181, mean (SD), pg/mL 34.16 (9.70) 33.20 (10.34) 94.00 (27.77) <0.001 
CSF TAUpThr231, mean (SD), U/mL 7.01 (4.84) 7.99 (4.08) 8.93 (8.59) 0.26 
Ratio Thr181/TAU, mean (SD) 0.16 (0.05) 0.14 (0.03) 0.11 (0.02) 0.002 
Ratio Thr231/TAU, mean (SD) 0.04 (0.02) 0.04 (0.03) 0.01 (0.01) 0.005 
 
 
The association between the studied proteins and age were analysed. As the samples 
followed a normal distribution, Pearson correlation coefficient was used. None of the proteins 
analysed (Aβ42, TAU, T181, T231) displayed any correlation with age (P = 0.078, 0.733, 0.765, 0.324 
respectively). The ratio of Thr181 with TAU and Thr231 with TAU did not correlate either (P = 0.210, 
P = 0.919, respectively) 
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Within the AD set was 4 early-onset AD patients (younger than 65 years). Statistical analysis 
did not reveal a significant difference in phospho-TAU231 levels between the early-onset and late-
onset AD patients (P = 0.22) nor with the Thr231/TAU ratio (P = 0.99). Thus, age does not appear to 
be a significant factor for TAU Thr231 phosphorylation levels in CSF. 
In relation to gender, we also saw no correlation with any of the proteins age (P = 0.078, 
0.733, 0.765, 0.324 respectively).  
We looked for statistical interactions between the analysed proteins level and ApoE ε4 
genotype carriers and gender, and concluded that there was a significant correlation between Aβ42, 
TAU and TAUpThr181 (P = 0.011, 0.010, 0.004, respectively) but not with TAUpThr231 (P = 0.604). 
The correlation of both ratios with ApoE was also analysed and again only Thr181/TAU was 
statistically significant (P = 0.032). 
While analysing the ApoE ε4 genotype of each group we noticed, as expected, that there is 
a significant difference between the AD group and non-AD group (P < 0.001), and between the 
Amyloid Pathology group and non-AD group (P = 0.011). 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Discussion 
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5. Discussion 
 
5.1 PhosphoTAU231 in SH-SY5Y cells 
 
In this study, we examined the putative function TAUpThr231 and how that might affect the 
protein’s localization in SH-SY5Y neuroblastoma cells. The value of TAUpThr231 as a potential AD 
biomarker was investigated. We addressed the effects of Aβ on TAU phosphorylation of this residue 
and found that the phosphorylation levels did not fluctuate with exposure to Aβ.  However, 
significant differences in basal TAUpThr231 and total TAU levels were shown in both undifferentiated 
and differentiated SH-SY5Y cells. This may indicate that the phosphorylation of Thr231 is not due to 
an increase of Aβ, but may be a relevant process in cell differentiation. TAU has been suggested to 
increase with cell differentiation as the expression of all six mature TAU isoforms are used as markers 
for adult neurons (103). A previous study found in a Western blotting analysis obtained from 
hippocampal neurons samples that after Aβ42 oligomer exposure, TAU Thr231 phosphorylation 
decreased within the first 3–8 h, returning to control levels within 24 h (104). There are studies on 
other TAU phosphorylation residues, Ser262 and Ser396, where an increase in expression of both 
phosphorylated proteins was observed (105). 
To see if this phosphorylation pattern was common to other TAU phosphorylatable residues, 
TAUpSer262 and TAUpSer369 were tested. The latter are all relevant AD epitopes since they are 
reported to be hyperphosphorylated at an early stage of AD. No significant changes were detected 
upon cell differentiation. Thus of the TAU residues tested only Thr231 increased with differentiation. 
Alternatively, treatment with RA in SH-SY5Y was previously shown to increase total TAU and TAU 
phosphorylated at Ser199, Ser202, Thr-205, Ser396, and Ser404 protein levels, all of which are 
hyperphosphorylated in Alzheimer’s Disease (106,107), but decrease the expression of TAU 
phosphorylated at Ser262 (108). Furthermore, protein levels of MAP-2 and β-Tubulin, all 
microtubule-associated proteins, were shown to increase with cell differentiation. These proteins 
have been previously identified as indicators of differentiation (109).  
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5.2 PhosphoTAU231 cellular localization  
 
Colocalization studies of TAUpThr231 with t-TAU in undifferentiated and differentiated SH-SY5Y 
cells were carried out in this study.  The differentiation of SH-SY5Y cells results in a cell population 
that is both morphologically and biochemically distinct from undifferentiated SH-SY5Y cells with 
apparent neuronal morphology with extensive neurite outgrowth. The majority of TAU localize in the 
cytosol. A previous study found that traditionally cultured cells treated with RA for 7 days display 
poor TAU staining, mainly localized around the nucleus (103).  
It is important to note that the expression levels and cellular localization of TAU are different in 
human adult brain neurons when compared to cultured cells. Thus, in mature neurons, TAU is mainly 
found in the axons whereas, in cultured cells, such as in this study, TAU is present throughout the 
cells including the cell soma (110). This intracellular localization of TAU has been also reported in 
other studies (103,108,111).  
In undifferentiated cells, TAUpThr231 has a preferentially nuclear localization and in 
differentiated cells its localization expands to the cytosol and neuritis, suggesting that it may be part 
of the differentiation program. PhosphoTAU co-localized with t-TAU especially in differentiated SH-
SY5Y cells. This co-localization reinforces the hypothesis that TAUpThr231 is translocated from the 
nucleus to the soma and neurites of SH-SY5Y cells with differentiation since the total TAU is located 
mainly outside the nucleus, as was previously mentioned (103). 
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5.3 TAUpThr231 levels in Human Sample 
 
The relevance of TAUpThr231 in human samples, as a potential biomarker, was addressed in 
plasma, serum and CSF. The ideal fluid to access biomarkers is blood because it circulates through 
all the organs and contains secreted proteins. In addition, the collection of blood is not as invasive 
as a lumbar puncture. Unfortunately, we could not efficiently detect the TAUpThr231 residue in 
neither plasma nor serum because of the interference of several blood abundant proteins, such as 
albumin, that masked our protein of interest even after several clearance procedures 
CSF analyses proved to be a better procedure for identifying TAUpThr231. While analysing a set 
of 50 CSF samples of AD and non-AD patients, we observed that the ratio of TAUpThr231/t-TAU 
levels significantly differentiated the AD group from the non-AD group. Moreover, TAUpThr231/t-
TAU ratio levels improved diagnostic accuracy in patients with AD compared to the commonly used 
pTAU181/t-TAU ratio levels. In accord with our findings, a study performed by Spiegel et al, showed 
that pTAU231 was superior to pTAU181 in the separation of AD from normal controls. Also, that the 
major performance difference between the two residues was found in the greater accuracy of 
pTAU231 in the classification of cognitively normal subjects yielded significantly fewer false positives 
(112). The relationship of Thr231 phosphorylation levels and of the ratio of Thr213/TAU with age, 
ApoE genotype and gender were also analysed and no significant correlation with neither of this 
variables was evident. These findings indicate that TAUpThr231/t-TAU ratio levels may be a valuable 
marker for the clinical diagnosis of AD, irrespective of age and gender.  
In these same CSF samples, Aβ peptide was found to be decreased in AD patients. A study found 
that the presence of cortical amyloid plaques was associated with lower levels of CSF Aβ42. The 
lower CSF levels of Aβ42 in AD patients compared with controls are believed to be caused by its 
accumulation in senile plaques, a classical hallmark in Alzheimer disease  (113). In addition, high 
protein levels of total TAU and TAU phosphorylated at Thr181 are observed in patients with AD. Total 
TAU has been successfully analysed in CSF since 1995, showing a significantly elevated concentration 
in AD patients compared with controls as well as in patients with other neurodegenerative disorders 
(114). Tau and Aβ in CSF represent the earliest and most intensively studied biomarkers. The 
decrease of CSFAβ42 and increase of TAU proteins are currently accepted diagnostic biomarkers of 
AD (35,115). Given that hyperphosphorylation of TAU is associated with the formation of NFTs, the 
increase seen in CSF samples of AD patients may indicate the presence or formation of tangles in AD 
patients.  
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The data in this report supports the analysis of the levels of phosphoTAU in CSF as a diagnostic 
biomarker for AD. Over the years, CSF levels of several epitopes of tau protein have been analysed 
by ELISA to determine potential biomarkers. Kohnken et al and Buerger et al both showed that 
Thr231 could discriminate between patients with AD and control subjects with an extremely high 
specificity (87,93). Other studies show the levels of Thr231 together with other residues such as 
Thr181 and Ser235, reporting that phosphorylated CSF -TAU levels were significantly higher in AD 
patients than those in non-AD controls (112,114,116).  
5.4 Future prospects and Challenges in biomarker discovery 
 
Future research and improvements can be made as the present study has several 
weaknesses and challenges given that our clinical AD sample size was relatively small and did not 
include subjects with other relevant conditions such as mild cognitive impairment.  There are still 
some crucial issues that need to be improved in order to achieve an optimal implementation of CSF 
biomarkers in clinical trials. On one hand, more observational longitudinal studies with larger sample 
sets are needed to determine the patterns of biomarker change along the natural course of the 
disease. Another constraint is the low concentration of TAU in CSF, ranging from approximately 300 
ng/L in healthy individuals to 900 ng/L in AD patients, falling close to the detection limit of most 
assays (117).  
In terms of cell culture, the future work arising from these studies may be to use different 
incubation times with Aβ peptide (0 to 24h) to better see its influence in the phosphorylation of TAU. 
Also, to use different time points in the differentiation program to see in which the translocation of 
the phosphorylated TAU happens. 
The challenges we faced were mostly during the blood analysis. Blood is comprised of 
multiple cellular compartments and an ever-changing environment of proteins, lipids, and other 
biochemical entities such as albumin, heparin or ethylenediamine tetraacetic acid (EDTA) that can 
impact biomarker stability and detectability. Several albumin removal methods should be used 
during the examination of serum and plasma protein content. Affinity chromatography techniques 
and trichloroacetic acid precipitation along with the methods based on the columns containing 
specific resin to remove albumin and immunoglobulin increases the chance to observe the proteins 
which are naturally in serum binding to albumin and globulins on the protein pattern (118). It is 
noteworthy that most of the work within the AD blood-based biomarker space remains in early 
discovery stage with only a few laboratories replicating across cohorts and even fewer attempting to 
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lock down methods for prospective studies. Several groups have identified promising signals in 
peripheral blood, suggesting that a blood-based AD screen may be on the horizon  (119–123). 
TAU is most closely related to neuronal death and is hypothesized to be fragmented in the 
blood. For more accurate results, biotechnology companies have been developing novel methods 
and technologies, with more overall sensitivity for biomolecules detection that could be used for 
future biomarker discoveries. Henriksen and colleagues described the recent development of a 
digital ELISA for total TAU in serum and suggest that this type of technology may also enable the 
detection of Aβ peptides (124). TAU levels in peripheral bodily fluids need more research for one to 
understand how the increased brain levels of TAU in AD might be reflected in elevated levels of TAU 
in blood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Conclusion 
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6. Conclusion 
 
There is an urgent need for a simple screening procedure that can identify patients with AD 
in a differential, inexpensive and non-invasive manner. The identification of novel and valid 
biomarkers in the peripheral fluids such as blood and CSF is highly desirable and can become an 
essential tool for diagnosing Alzheimer's disease. 
The work here describes the TAU Thr231 phosphorylation potential as a biomarker for AD, 
but also its function and its contribution to TAU localization in SH-SY5Y neuroblastoma cells 
The experimental data revealed that cellular differentiation induced by treatment with RA 
increased expression of TAU phosphorylated at Thr231. In undifferentiated SH-SY5Y cells, pTAU231 
was located mainly in the nucleus and, in contrast, TAU and pTAU231 were redistributed in the 
neurites and in the soma of SH-SY5Y cells induced to differentiate by retinoic acid (RA). This appears 
to suggest that the phosphorylation of the Thr231 residue may be a relevant process in cell 
differentiation. 
As a CSF biomarker, the ratio of pTAU231/TAU levels discriminated significantly the AD group 
for the non-AD group. Moreover, TAUpThr231/t-TAU ratio levels improved diagnostic accuracy when 
compared with the mostly used pTAU181/t-TAU ratio levels in patients with AD.   
These findings indicate that pTAU231/t-TAU ratio levels may be a valuable marker for the 
clinical diagnosis of AD, irrespective of age and gender. 
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I. Cell Culture Reagents and Equipment 
Equipment 
 
 Hera cell CO2 incubator (Heraeus) 
 Safety cabinet Hera safe (Heraeus) 
 Inverted optical microscope (LEICA) 
 Hemacytometer (Sigma) 
 Sonicator (U200S (IKA)) 
 Bath SBB6 (Grant) 
 
Solutions 
 
 SH-SY5Y Complete Medium (Eagle’s Minimum Essential Medium/F12 Medium 1:1) 
-  4.805 g MEM 
-  5.315 g F12 
-  1.5 g NaHCO3 
-  0.055 g Sodium Pyruvate 
-  10 mL Streptomycin/Penicillin/Amphotericin solution 
-  100 mL 10% FBS 
-  2.5 mL L-glutamine (200 mM stock solution) 
Dissolve in deionized H2O. Adjust the pH to 7.2-7.3. Adjust the volume to 1000 mL with deionized 
H2O. 
For other combinations of FBS, replace 100 mL FBS with 10 mL (1% FBS MEM:F12) or remove FBS 
(serum-free MEM:F12). 
 
 PBS (1x)  
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate Buffered 
Saline Pack (Pierce) in deionised H2O. Final composition:  
- 8 mM Sodium Phosphate  
- 2 mM Potassium Phosphate  
- 140 mM Sodium Chloride  
- 10 mM Potassim Chloride  
Sterilize by filtering through a 0.2 μm filter and store at 4oC.  
 
 Trypsin-EDTA 0,05% (Thermo) 
 
 Trypan Blue solution cell culture tested (Sigma) 
 
 RIPA buffer  
To 980 μL of RIPA buffer (Sigma-Aldrich) add:  
- 20 μL Protease inhibitor cocktail (Roche)  
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 Beta-Amyloid 1-42, TFA (GenicBio) 
 
II. Protein Content Determination 
Equipment 
 Tecan 5000 
 
Reagents 
 BCA assay kit (Pierce, Rockfort, IL) 
 Bovine Serum Albumin (BSA) (Pierce)  
 Working Reagent (WB) (50 Reagent A : 1 Reagent B) 
o Reagent A: sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 
0,2N sodium hydroxide 
o Reagent B: 4% cupric sulfate 
 
III. SDS-PAGE  
 
Equipment 
 Electrophoresis system (Hoefer SE600 vertical unit) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents 
 
 Acrylamide: Bis-Acrylamide 29:1 solution 40%, Dnase, Rnase free (Fisher) 
 
 10% APS (ammonium persulfate)  
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use.  
 
 10% SDS (sodium dodecilsulfate)  
In 10 ml of deionised H2O dissolve 1 g of SDS.  
 
 LGB (Lower gel buffer) (4x)  
To 900 ml of deionised H2O add:  
- 181.65 g Tris  
- 4 g SDS  
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L with 
deionised H2O.  
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 UGB (Upper gel buffer) (5x)  
To 900 ml of deionised H2O add:  
- 75.69 g Tris  
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L with deionised 
H2O.  
 
 Loading Gel Buffer (4x)  
- 2.5 mL 1 M Tris solution (pH 6.8) (250 mM)  
- 0.8 g SDS (8%)  
- 4 ml Glicerol (40%)  
- 2 ml Beta-Mercaptoetanol (2%)  
- 1 mg Bromofenol blue (0.01%)  
Adjust the volume to 10 ml with deionised H2O. Store in darkness at room temperature.  
 
 1 M Tris (pH 6.8)  
To 150 ml of deionised H2O add:  
- 30.3 g Tris base  
Adjust the pH to 6.8 and adjust the final volume to 250 ml.  
 
 10x Running Buffer  
- 30.3 g Tris (250 mM)  
- 144.2 g Glycine (2.5 M)  
- 10 g SDS (1%)  
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1 L.  
 
 Stacking (upper)  and Resolving (lower) gel solution   
 Stacking Gel Resolving Gel 
 3.5% 5% 20% 
- H2O 13.83 ml 18.59 ml 7.34 ml 
- 29:1 Bis-Acrylamide 1.75 ml 3.75 ml 15 ml 
- LGB (4x) - 7.5 ml 7.5 ml 
- UGB (5x) 4.0 ml - - 
- 10% APS 200 μL 150 μL 150 μL 
- 10% SDS 200 μL - - 
- TEMED 20 μL 15 μL 15 μL 
 20 mL 60 mL 
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IV. Western-Blotting Solutions and Equipment  
 
Equipment 
 Transphor Electrophoresis unit (Hofer TE 42) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacie Biotec) 
 
Reagents 
 
 1x Transfer Buffer  
- 3.03 g Tris (25 mM)  
- 14.41 g Glycine (192 mM)  
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 ml with 
deionised H2O. Just prior to use add 200 ml of methanol (20%).  
 
V. ImmunoBlotting Solutions  
 
Equipment 
 ChemiDoc Touch Imageing System (BioRad) 
 
Reagents 
 10x TBS (Tris buffered saline)  
- 12.11 g Tris (10 mM)  
- 87.66 g NaCl (150 mM)  
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O.  
 
 10x TBS-T (TBS+Tween)  
- 12.11 g Tris (10 mM)  
- 87.66 g NaCl (150 mM)  
- 5 ml Tween20 (0.05%)  
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O.  
 
 Blocking solution  
5% of nonfat dried milk or BSA (Bovine Serum Albumine, Sigma) in 1x TBS-T. 
 
 Amersham ECL Select Western Blotting Detection Reagent (GE Healthcare Life Sciences) 
 
 Membranes Stripping Solution (500 ml)  
- 3.76 g Tris-HCl (pH 6.7) (62.5 mM)  
- 10 g SDS (2%)  
- 3.5 ml Beta-mercaptoetanol (100 mM)  
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the mercaptoethanol and 
adjust volume to 500 ml. 
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VI. Immunoprecipitation 
 
 Dynabeads® Protein G (Thermo Science) 
 
 Blocking solution  
Add 0.6g of BSA (Bovine Serum Albumine, Sigma) to 20 mL of PBS 1x. 
 
VII. Imunocitochemistry 
 
 Blocking solution  
5% BSA (Bovine Serum Albumine, Sigma) in 1x PBS. 
 
 Permeabilization solution 
0.2% Triton X-100 Surfactant (Calbiochem) in 1x PBS. 
 
 Fixing solution 
4% PFA  (Paraformaldheyde, Sigma) in 1x PBS 
 
VIII. ELISA 
 
 Human TAU [pT231] PhosphoELISA™ Kit, Invitrogen 
 INNOTEST PHOSPHO-TAU [181P] Antigen, Innogenetics  
 INNOTEST hTAU-Ag, Innogenetics 
 INNOTEST β-amyloid [1-42], Innogenetics 
 
IX. Albumin/IgG depletion 
 
 ProteoSeek columns (IgG removal kit, Thermo Science) 
 
 
 
